Abstract
Primary Sjögren’s syndrome (pSS) is a chronic autoimmune disease primarily affecting exocrine glands such as the salivary glands, leading to impaired secretion and sicca symptoms. As the mainstay of salivation, salivary gland epithelial cells (SGECs) have an important role in the pathology of pSS. Emerging evidence suggests that the interplay between immunological factors and SGECs may not be the initial trigger or the sole mechanism responsible for xerostomia in pSS, challenging conventional perceptions. To deepen our understanding, current research regarding SGECs in pSS was reviewed. Among the extensive aberrations in cellular architecture and function, this review highlighted certain alterations of SGECs that were identified to occur independently of or in absence of lymphocytic infiltration. In particular, some of these alterations may serve as upstream factors of immuno-inflammatory responses. These findings underscore the significance of introspecting the pathogenesis of pSS and developing interventions targeting SGECs in the early stages of the disease.
Graphical Abstract
Similar content being viewed by others
Introduction
Primary Sjögren’s syndrome (pSS) is a prevalent chronic autoimmune disease characterized by lymphocytic infiltration in exocrine glands, primarily involving the lacrimal and salivary glands. The majority of pSS patients suffer from dryness, pain and fatigue, while 30–40% may develop systemic manifestations over time. Compared to the general population, pSS patients face a substantially increased risk of lymphoma, which poses a threat to their overall survival [1, 2].
Xerostomia is a hallmark symptom of pSS, affecting more than 90% of the patients [3, 4]. Salivary flow in pSS patients is notably reduced compared to those only with sicca symptoms [5]. Inadequate salivary secretion can further cause burning sensation in the mouth, oral infections, frequent ulcers, and rampant caries, ultimately resulting in difficulties with swallowing or speaking. These challenges tremendously diminish patients’ quality of life [6, 7].
Unfortunately, there is scant robust evidence hitherto indicating that current immunological interventions for pSS effectively alleviate oral dryness. Regarding conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), studies have shown limited efficacy of the mainstream treatment hydroxychloroquine in managing pSS [8,9,10]. Other csDMARDs such as methotrexate [11], cyclosporine [12] and leflunomide [13] have also demonstrated minimal improvement in objective secretory function. In terms of biologics, tumor necrosis factor inhibitors [14, 15], anti-CD20 agent rituximab [16,17,18,19,20], B-cell activating factor inhibitor belimumab [21,22,23], the selective T-cell co-stimulation modulator abatacept and the CD40 inhibitor [24, 25] have yielded similarly unsatisfactory results in enhancing salivary secretion.
The disappointing efficacy of these interventions may be attributed to accumulating evidence suggesting that progression of the disease and lymphocytic infiltration do not necessarily parallel secretory dysfunction [26,27,28,29,30]. Studies have demonstrated no significant difference in focus score between pSS patients without dryness and those experiencing extreme dryness [31]. Similarly, regardless of the presence of germinal centers, which indicate more severe lymphocyte aggregation in salivary glands (SGs), salivary secretion did not differ significantly [32].
Epithelial cells, as the central players in the pathogenesis of autoimmune diseases, have garnered significant attention from researchers in recent years. Some scholars propose that both pSS and primary biliary cholangitis (PBC) fall under the spectrum of generalized autoimmune epithelitis [33,34,35,36]. Both diseases predominantly affect peri-menopausal women and have a frequent coexistence in clinical practice. Histologically, these two conditions are characterized by infiltration of B and T cells affecting exocrine glands and biliary epithelium, respectively. There is a certain degree of serological overlap between the two diseases, with detectable antinuclear antibodies, anti-Ro-52 antibody, and anti-centromere antibody. Immunosuppressive therapy also has shown limited efficacy for PBC, emphasizing the significant role of non-immunological pathology of epithelial cells in the pathogenesis.
This review will focus on pSS to illustrate the role of salivary gland epithelial cells (SGECs), looking for clues in viral infection, epigenetic dysregulation, structural disorder, secretory dysfunction, signaling pathways aberrations, homeostasis disruption, etc. We aim to offer novel perspectives, and cast a new light on future research into mechanisms and clinical treatment of pSS.
Physiology of saliva secretion
Saliva serves numerous essential functions within the buccal cavity including flushing, bacteriostasis, and lubrication [37]. SGECs play a pivotal role of salivation [38], with acinar epithelial cells primarily responsible for secreting isotonic saliva, which is then modified by ducts and transported into the mouth. Surrounding ductal and acinar epithelium, myoepithelial cells contribute to the expulsion of saliva through contraction.
Structure of SGECs
Epithelial cells are densely arranged and form the epithelium of SGs. SGECs exhibit polarization along the apical–basal axis, with the apical pole facing the lumen and the basal pole directed towards the deep connective tissue [39]. The apical membrane is equipped with microvilli and cilia to aid in mucus drainage. Additionally, aquaporins (AQPs), associated ion transporters and channels are also present in the apical membrane to facilitate fluid and electrolyte efflux. The basement membrane (BM) is located between the basal surface of the epithelium and the deep connective tissue. SGECs feature narrow cell gaps on the lateral sides, with extracellular matrix (ECM) in between, forming selectively permeable extracellular barriers between adjacent cells. The lateral membrane is tightly interconnected by cell junctions.
Cell junction is a specialized structure, which can be categorized into three groups: tight junctions (TJs), gap junctions (GJs), and anchoring junctions [40]. Anchoring junctions are further divided into desmosomes, hemidesmosomes (HDs), and adherens junctions (AJs). TJs serve as major intercellular junctions, forming barriers between epithelial cells essential for cell polarization and limiting paracellular permeability [41]. GJs facilitate intercellular communication and substance exchange. AJs and desmosomes reinforce cell adhesion, contributing to epithelial tissue integrity. HDs, located on the basal surface of the epithelium, connect the BM to the ECM. Cell junctions contribute substantially to cell polarity, which is important in directing secretion and absorption.
Secretory process in SGECs
Ninety-nine percent of the final saliva is composed of water, with the remaining portion comprising various proteins and electrolytes. Salivation is a sophisticated process in SGECs. It is regulated by autonomic nerves, with neurotransmitters serving as the first messengers of salivary secretion, notably acetylcholine (ACh) and adrenaline [42].
Fluid and electrolyte secretion
In the main SGs, fluid and electrolyte secretion depend on cholinergic signals from the parasympathetic nerves [38]. ACh binds to the muscarinic receptors, initiating the activation of phospholipase C (PLC) and hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2). PIP2 hydrolysis generates 1,4,5-triphosphate (IP3), which acts as the second messenger to trigger the elevation in intracellular Ca2+ concentration ([Ca2+]i) by binding to IP3R receptors (IP3Rs) [43]. As crucial Ca2+ channels within cells, IP3Rs mediate the rapid release of Ca2+ from endoplasmic reticulum (ER), and determine the initiation and pattern of Ca2+ signaling [44].
The Ca2+ signaling cascade is further amplified by store-operated calcium entry (SOCE). SOCE is mediated by Ca2+ release-activated Ca2+ (CRAC) channels, with STIM1, Orai1, and TRPC identified as pivotal components. STIM1 senses the consumption of Ca2+ in ER, leading to the interaction between STIM1 and Orai1, and subsequently recruiting TRPC channels. This process forms CRAC channels, enabling enormous Ca2+ influx and rapidly augmenting the elevation of [Ca2+]i [45].
The augmentation of Ca2+ signals ultimately trigger salivary fluid and electrolyte secretion. The steep rise in [Ca2+]i stimulates Ca2+-activated Cl− channels ANO1 and K+ channels, and meanwhile evokes the transportation of AQP5 to the apical membrane [46]. Concurrently, during ion exchange, Na+/K+-ATPase hydrolysis sustains high intracellular K+ concentrations and extracellular Na+ concentrations, establishing a decreased Na+ chemical gradient inwardly [43]. As a result, water passes through paracellular transport or AQP5 into the lumen. Together with Cl− channels on the apical membrane allowing Cl− efflux, this process generates primary saliva highly enriched in NaCl is produced. Subsequently, in ductal cells, ion channels reabsorb Na+ and Cl− while secreting small amounts of K+ and HCO3−, leaving the saliva hypotonic [47].
Protein secretion
Protein secretion is regulated by sympathetic nerves in SGs. The stimulation of β1-adrenergic receptor induces exocytosis of protein storage granules via the cAMP/PKA pathway [38]. During exocytosis, SNARE proteins play a crucial role in membrane trafficking and fusion [48]. Mucins, primarily MUC5B and MUC7 in human saliva, are the major proteins released through exocytosis [49]. Their main function is to preserve oral cavity moisture [50].
Viral infection and SGECs
Viral infection and its possible contribution to pSS development have been studied for years. Currently, there is evidence suggesting that Epstein–Barr virus (EBV) and human T-cell leukemia virus type 1 (HTLV-1) infections are related to SGECs in pSS.
EBV has been most explicitly studied as a candidate directly inducing the phenotype discovered in pSS. EBV infects oral epithelial cells, replicates within them to produce progeny viral particles, and eventually leads to cell apoptosis and antigen release [51]. It was found that EBV-encoded small RNA binds to the SS autoantigen La/SSB, subsequently activating toll-like receptor (TLR)-3 and leading to production of proinflammatory cytokines [52]. Meanwhile, EBV can shuttle between epithelial cells and B cells, spreading the infection to B cells. As the lytic infection fades, a small amount of EBV can establish lifelong latent infection in memory B cells. This latent infection can be reactivated in response to environmental factors, and chronic or relapsing EBV infection in epithelial cells is associated with pSS [53]. It is recently established that EBV-specific microRNA (ebv-miR-BART13-3p) [54] exert their functions on SOCE, which will be discussed and illustrated in “The defect of calcium signaling” section and Fig. 2.
HTLV-I is believed to directly infect SGECs, causing alterations in cellular functions and inducing inflammation [55]. HTLV-1 virus particles are transmitted to SGECs through biofilm-like structures [56]. Infected cells produce molecules such as ICAM-1, IP-10, and RANTES, which are involved in adhesion, inflammation and migration [55, 57].
Although compelling evidence regarding viruses as environmental triggers for pSS is still lacking, their interactions with SGECs appear to partly mediate the emergence of the pSS phenotype.
Epigenetic dysregulation in SGECs
Epigenetics encompasses heritable yet reversible alterations in phenotype not rooted in DNA sequence, including DNA methylation, non-coding RNAs, and histone modifications. In pSS, changes in DNA methylation and microRNAs are observed in SGECs.
DNA methylation dysregulation
In SGECs from pSS patients, there is an overall decrease in DNA methylation level, contrasting with unaffected levels in T and B cells [58]. This suggests a preferential impact of epigenetic inheritance on epithelial cells. The DNA methylation deficit correlates with cytokeratin 19 [59] and ten-eleven translocation 2 (TET2) [60]. TET2 overexpression induces DNA hydroxymethylation, prompting demethylation associated with inflammation [60].
Consequently, SGEC dysfunction may partly result from altered DNA methylation level. For example, demethylation at the SSB gene promoter correlates with the overexpression of anti-SSB/La [61]. Moreover, the calcium pathway (involved in salivation, see details in “The defect of calcium signaling” section) experiences demethylation in SGECs, while the Wingless (Wnt) pathway (involved in cell survival and differentiation, see details in “Wnt and Hippo signaling pathway” section) undergoes methylation [62].
MicroRNA dysregulation
Several studies reveal significant alterations in microRNA expressions in pSS in comparison to healthy controls, contributing to SGEC dysfunction and the emergence of immune characteristics. In one analysis, let-7b microRNA expression was downregulated in SGECs of autoantibody-positive pSS patients compared to negative patients [63]. Since let-7b microRNA can repress the transcriptional regulation of autoantigens SSA/Ro and SSB/La, its downregulation is implicated in their transcriptional dysregulation. Another study reported upregulation of miR-200b-3p in SGECs of pSS patients compared to sicca-complaining group, negatively correlating with Ro60/TROVE2 mRNAs in SGECs [64]. In an SS-susceptible mouse model, miR-146a expression was shown upregulated in the SGs at both 8 weeks (early phase of disease) and 20 weeks (late phase of disease) of age [65]. Further studies indicate that co-stimulatory molecule CD80 in SGECs is a potential target directly inhibited by miR-146a, thus altering CD86: CD80 ratio [66]. Moreover, miR-1248 [67] exerts its functions on SOCE, which will be discussed and illustrated in “The defect of calcium signaling” section and Fig. 2.
Structural disorders of SGECs
The SG possesses a delicate structure that often faces disorder or even destruction in pSS patients. Multiple imaging techniques have frequently detected abnormal changes in SG tissue structure such as sialectasis, sparsity of the ductal branching pattern, and fat replacement [68,69,70]. The macrostructural changes in the SGs serve as indicators of microstructural changes in the epithelium. Evidence demonstrates that SGECs undergo considerable structural changes in their apical, lateral and basal structure as well as in the ECM, causing loss of barrier function and cell polarity, consequently resulting in dysfunction (see Fig. 1).
Changes in the apical membrane
The alterations in the apical pole of SGECs mainly involve microvilli and AQP5, which share a common mechanism involving ezrin aberration.
An early study revealed a decrease in the number of microvilli on the apical surface, accompanied by a loss of their typical finger-shaped morphology [71]. Microvilli morphology is dependent on F-actin and is regulated by ezrin and its phosphorylated form. In control samples, ezrin was predominantly located in the apical area. In the acini of pSS patients, however, there is a significant increase in the expression of ezrin and P-ezrin, most of which is observed in the basal region rather than the apical pole. This shift in apical–basal cytoplasmic distribution [72] likely contributes to the disruption of the microvilli structure.
Regarding AQP5, its mislocation can be observed in acinar cells of pSS patients, which also seems to be partially associated with ezrin. In a study, researchers demonstrated protein–protein interactions between ezrin and AQP5, with their complexes found to be mislocalized to the basolateral region rather than the apical region in the acini of pSS [73].
Changes in the lateral membrane
TJs on the lateral membrane are primarily engaged in the pathology of pSS. These TJs consist of both plasma membrane and cytosolic components. A notable decrease in the integrity of key proteins within this complex, such as occludins, ZO-1, claudins-1, -3 and -4, has been observed in SGECs affected by pSS [74]. At the genetic level, a study demonstrated apparent alteration in the genes encoding TJ proteins during the pre-autoimmune phase of the disease with phenotype resembling SS in C57BL/6.NOD-Aec1Aec2 mice. These genes include TJP1, TJP2, AMOTL1, IGSF5, CLDN3, CLDN7, CLDN8 and CLDN12 [75]. Such genetic disturbances suggest a disruption in the permeability of epithelial barriers, potentially leading to SGEC malfunction before immunoinflammatory responses. Of note, TJ disorder can trigger the loss of microvillus configuration, as microvilli and TJs are connected via F-actin [76].
Changes in the BM
Labial salivary glands (LSGs) from pSS patients show tremendous changes in the BM, characterized by structural disorganization and loss of individual constituents [77]. Meanwhile, anoikis, a form of programmed cell death triggered by the separation of cells from ECM, has been identified in SGECs affected by pSS [78]. This phenomenon might be attributed largely to detachment of the epithelial cells and basal lamina [71]. Such events facilitate the invasion of inflammatory cells and trigger subsequent responses.
BM contains various components such as members of the laminin family, type IV collagen, and nidogens [79]. Laminin, the most abundant glycoprotein in BM, plays a role in maintaining epithelial cell polarity while mediating inflammation under certain circumstances [80]. Previous studies have reported overexpression of laminin-1 and -5, increased nidogen hydrolysis, and disturbances in the BM of SGs in pSS patients [77, 80,81,82,83]. Significant increases in both laminin mRNA and protein level were observed compared to normal controls, which took place devoid of periductal lymphocytic foci [80]. Elevated levels of laminin mRNA and protein, along with increased degradation of nidogens, indicated active remodeling of the BM. Such phenomena were less prominent in patients with a high degree of fibrosis and low salivary flow [81]. The BM disorganization might be partly attributed to the deteriorating effect of matrix metalloproteinases (MMPs). Previous studies have demonstrated enhanced activation of MMPs in acinar and ductal epithelial cells of LSGs from pSS, particularly showing an imbalance in the ratio of MMP-9 to its tissue inhibitor within the cytoplasm [71, 84]. As a consequence, the basal lamina becomes disorganized with degradation of laminin and type IV collagen.
In addition, cell–BM interactions such as HDs also contribute to basal structural disorder. Two main types of hemidesmosomes are identified in epithelia. Type I HDs consist of the integrin α6β4, protein BP180, CD151, BP230 and plectin, interacting with cytokeratin filaments, whereas type II HDs consist only of integrin α6β4 and plectin [85]. Alterations in these components are commonly observed in the SGs of pSS patients. Hypermethylation of the BP230 gene and an increase in BP230 protein level have been found in the acini of LSGs from pSS patients, while the BP180 protein level showed the opposite trend [86]. Meanwhile, α6β4 expression was observed not only in the basal laminae, but also in the cytoplasm and lateral plasma membrane [87]. Collectively, these results indicate substantial alterations in HDs and disorganization of the basal lamina, which may hinder ECM–cell communication.
In summary, the findings indicate that the early development of pSS is accompanied by regenerative processes of BM in SGECs. Immunoinflammatory involvement is facilitated due to structural disorder, which reciprocally causes more extensive changes of BM, resulting in anoikis of SGECs and glandular destruction.
ECM remodeling
ECM is of great importance in cell survival, maintaining cellular structure and function, and mediating signal transductions [88, 89]. Physiological remodeling of ECM components (laminin and type IV collagen) depends on a delicate balance between proteolytic enzymes and their inhibitors [90]. Pronounced ECM destruction has been detected in the LSGs of pSS patients [88], while excessive or uncontrolled ECM destruction can disrupt the structure of the parenchymal cells and lead to severe tissue dysfunction [91]. Previous research has shown that the proteolytic activity of MMP-1, MMP-3 and MMP-9 on ECM macromolecules was significantly enhanced in LSGs extracted from SS patients. Interestingly, such changes occur concurrently with the loss of microvilli and disorders in BM, independent of the presence or the proximity to inflammatory cells [71, 88]. The aberrant degradation of ECM promotes the release of soluble damage associated molecular patterns (DAMPs), which can be recognized by B cells and activate Myd88-dependent signaling pathways. This may partly explain the underlying mechanism of B cell activation in pSS [92].
Aberrations in salivary secretory process
Inadequate salivation is the culprit of xerostomia in pSS. Extensive research has been conducted over the decades to examine both fluid and protein secretion.
Aberrations in fluid secretion
Given that water makes up 99% of saliva, aberrations of fluid secretion are considered to make utmost contribution to hyposalivation. The deviations may take place in the activation of muscarinic receptor, Ca2+ signaling, and apical channels (see Fig. 2).
The abnormal activation of muscarinic receptor
The initiation of signal transduction in the secretory process is attributed to the release of neurotransmitters and the activation of M3 muscarinic ACh receptor (M3R). Studies regarding innervation have shown no apparent loss of parasympathetic and sympathetic nerves, nor significant changes in distribution of immunoreactivity markers [93, 94], thus largely excluding the possibility of glandular denervation as a cause of secretory dysfunction in pSS. However, impaired neurotransmitter release or receptor binding has been observed in SGs. One study [95] showed that the acinar cells exhibited hyper-responsiveness to exogenous secretagogues, demonstrating their ability to function under certain stimulation, yet neurotransmitter release appeared to be somehow compromised. Another study suggested that it was the raised level of cholinesterase that mediated the metabolization of ACh, exerting an antisecretory effect in pSS [96].
In addition to neurotransmitters, malfunction of M3R represents another pathological factor. Upregulation of M3R in acinar cells, as demonstrated in one study [97], echoes with the hypersensitivity observed in the aforementioned experiment [95]. This up-regulation may result from impaired neurotransmission or blockade of M3R. Massive evidence has proved the existence of auto-antibodies in the serum of pSS patients targeting at extracellular loops of M3R [98,99,100]. By irreversibly binding to the second extracellular loop of M3R, most of these auto-antibodies act as antagonists of M3R. However, an increase in agonistic functional auto-antibodies targeting the first extracellular loop has also been detected [100]. The coordination and precise impact of these auto-antibodies on the hypofunction of SGs remain incompletely understood. Variants of the CHRM3 gene, which encodes M3R, also appear to have potential associations with an increased risk of pSS, further highlighting the relevance of M3R in the pathogenesis of the disease [101].
The defect of calcium signaling
Subsequent to the signal transduction, inadequate Ca2+ signaling contributes substantially to the aberrations of secretory process in pSS. Studies have shown that acinar cells from pSS patients require a higher concentration of ACh to achieve the same Ca2+ mobilization [102], suggesting defects in Ca2+ signaling.
One important factor contributing to secretory dysfunction in Ca2+ signaling is the deficit of inositol trisphosphate receptors (IP3R). An enlightening study found that the acinar area unaffected by lymphocytic infiltration displayed a decrease in IP3R2 and IP3R3, without alterations in STIM1 or AQP5 [103]. This study unearthed early pathological changes in the gland, even before significant lymphocytic infiltration and tissue damage, can lead to hypofunction. Another study linked immune-dependent pathways with IP3R deficit through the dual functions of miR-1248 [67]. This microRNA inhibits the translation of IP3R and also induces interferon (IFN) production, resulting in suppression of Ca2+ signaling and stimulation of IFN signaling simultaneously.
Similar to IP3R, the ryanodine receptor (RyR) is also Ca2+-sensitive and modulates Ca2+ release from intracellular stores [104]. The regulation of RyR is influenced by cyclic adenosine diphosphate (cADP) ribose concentration, which is controlled by cyclic guanosine monophosphate (cGMP) [105]. Increased levels of nitric oxide (NO) have been observed in the serum of pSS patients [106], and NO participates in RyR modulation through the cGMP/ADPr/RyR pathway. The effects of NO on RyR activity depend on the duration of exposure [104]. Temporary elevation of NO leads to an increase in Ca2+ signal through the activation of RyR via cGMP. Prolonged elevation of NO, however, significantly reduces RyR activity independent of cGMP, probably through direct nitrosylation of RyR.
The aberration of SOCE holds significant importance in autoimmune diseases [141], and can cause the failure of Ca2+ signal augmentation. In the preliminary phase of pSS, a study demonstrated that an EBV-specific microRNA, ebv-miR-BART13-3p, targets the Ca2+ sensor STIM1, leading to attenuated SOCE [54]. This highlights the connection between viral infection and salivation loss, in which case immunoinflammatory responses are unnecessary.
Additionally, there have been reports of decreased expression of SERCA2b, a type of Ca2+ pump in ER, was also reported [107], although explicit evidence is limited.
Taken together, the evidence reveals that alterations in Ca2+ mobilization and subsequent hyposecretion are not necessarily consequences of immunoinflammatory responses.
The dysfunction of apical channels
The channels present in the apical membrane of SGECs, including ion channels and AQPs, serve as effectors of preceding pathways. Upon activation of muscarinic receptors and Ca2+ movement, the direct consequence is the translocation of AQPs to the apical membrane and an increase in ion channel activity [102, 108]. Theoretically, any pathological factors that interfere with neurotransmission and Ca2+ mobilization would influence ion transport and water permeability.
A common observation in various experiments is the mislocalization of AQPs due to erroneous trafficking. Instead of predominant distribution in apical membranes, AQP5 is remarkably expressed in basolateral membranes of SGECs of both model mice and human subjects with SS [109,110,111,112]. While there is controversy regarding whether AQP distribution has been altered [103, 113, 114], a significant body of evidence tends to support this phenomenon. Indeed, a majority of studies investigating ACh, M3R and Ca2+ mobilization mentioned above have observed AQP localization and acquired positive results.
Ions not only comprise the composition of saliva, but also serve as the driving force for water permeation. It was confirmed in acinar cells affected by pSS that the activation of Ca2+-dependent K+ channels and Cl− channels is disrupted [102]. This disruption leads to a loss of the driving force for water efflux, consequently resulting in reduced salivary secretion.
Aberrations in protein secretion
Abnormal protein secretion, particularly mucin exocytosis, may provide some rationale for the occurrence of pSS (see Fig. 2). It has been observed that in pSS patients without a significant decrease in salivary flow, the reduction of mucins in saliva can still cause severe xerostomia. This could be attributed to both the decreased quality of mucins and aberrations in the trafficking route [115]. Regarding the quality of mucins, it has been demonstrated that sulfotransferase Gal3ST activity markedly decreases in SGECs of pSS patients, resulting in hyposulfated mucins that are unable to retain moisture [116]. As for abnormal exocytosis, it is probably a consequence of sabotage of cellular structure. Exocytosis requires the participation of Rab family GTPases and SNARE proteins. In pSS patients, Rab3D and SNARE proteins such as VAMP8, syntaxin (STX) 3, STX4 and SNAP23 were relocated from the apical to the basal area of acinar cells, disrupting the cell polarity of SGECs. This leads to the aggregation of mucins in the cytoplasm and ECM rather than secretion into the duct [117, 118]; therefore, the amount of mucins in saliva is insufficient for lubrication and moisturization of the oral cavity. Moreover, the mis-distributed mucins (MUC5B and MUC7) mimic the role of DAMPs in stimulating the TLR4 signaling pathway and initiating inflammatory responses [119]. It should be noted that the compensatory increase in mucin synthesis in SGECs could exacerbate and perpetuate the inflammatory responses [120].
Alterations of signaling pathways
As the center of the onset and progression of pSS, SGECs have undergone alterations in multiple signaling pathways to some extent. Previous studies have heavily emphasized immunological pathways such as NF-κB signaling, IFN pathways, TLR pathway, etc. [121]. Nevertheless, a few other pathways related to the functions of SGECs are gaining increased attention. Interestingly, abundant evidence suggests that these alterations are more deeply involved in the pathogenesis of pSS, with varying degrees of direct interrelationship with immunoinflammatory responses.
Epidermal growth factor (EGF) signaling pathway
In the saliva of pSS patients, significantly low levels of EGF have been detected, which are related to the deterioration of saliva quality and severe intraoral manifestations [6]. An enhanced expression of the EGF/EGFR system, however, has been reported in SG samples extracted from pSS patients [122]. EGF is more than just a hormone secreted into exocrine fluid to stimulate growth, maintain functions, and defend against injury of gland epithelia. It can also be pro-inflammatory while anti-apoptotic, and may interfere with salivary secretion if it functions intracellularly.
EGF and its family play a complex and double-sided role in SGECs of pSS patients. They participate in the induction of inflammation in SGECs. The metalloproteinase ADAM17 promotes its family member amphiregulin to activate the EGF signaling pathway. As a result, extracellular signal-regulated kinase (ERK) 1/2 is phosphorylated to facilitate the release of inflammatory cytokines in pSS [123]. A few other studies, however, have suggested that EGF signaling could biologically function to prevent apoptosis in pSS. Stimulation of M3R by carbachol leads to the activation of EGFR mediated by Src, subsequently phosphorylating ERK and Akt pathways and suppressing apoptosis mediated by caspase 3/7 [124]. EGF was also proved to activate PI3K-Akt and NF-κB via distinct pathways to exert anti-apoptotic impact on SGECs [125].
Transforming growth factor (TGF)-β signaling pathway
Epithelial–mesenchymal transition (EMT), a process whereby epithelial cells transition into a mesenchymal phenotype with inhibited expression of the epithelial marker E-cadherin and elevated vimentin expression, is recognized as the primary mechanism of fibrosis in SGs in pSS [126]. TGF-β has garnered increased attention in the study of pSS development due to its role in eliciting EMT and fibrosis in SGs. One study demonstrated an elevation of TGF-β1 protein in SG tissues in pSS compared to those of healthy controls [127]. The TGF-β signaling pathway can be triggered by TGF-β cytokine family, including bone morphogenetic protein (BMP). TGF-β or BMP binds to receptors, which phosphorylate SMAD2 and 3, or SMAD1, 5, and 8, forming complexes with SMAD4 that translocate into the nucleus. This leads to the activation of Snail, a transcriptional repressor of E-cadherin and a promotor of EMT [128]. In the non-canonical pathways of TGF-β, downstream factors such as RAS/RAF/MEK/ERK can also facilitate EMT in a SMAD-independent manner. Interestingly, IFN-γ/JAK/STAT pathway could activate SMAD7, known as the “anti-SMADs”, to repress TGF-β signaling pathway [129]. This may implicate an unconventional perspective on the role of the TGF-β and IFN-γ/JAK/STAT pathway, since JAK inhibitors are traditionally considered therapy for pSS patients yet with ambiguous efficacy.
Among the TGF-β superfamily, BMP might provide promising prospect for pathogenesis study and therapy development for pSS. Analysis of LSG epithelia from eight pSS patients and eight non-SS controls by RNA sequencing revealed upregulation of BMP related genes [130]. Another study also confirmed that BMP-6 increased in SGs of pSS patients and possibly induced SG hypofunction irrespective of immune activation and autoantibody production [131]. The increase in BMP-6 is correlated with the overexpression of lysosome-associated membrane protein (LAMP)-3, lysosomal exocytosis of heat shock protein 70, and subsequently induced TLR4 signaling [132, 133].
Wnt and Hippo signaling pathway
The Wnt signaling pathway contributes to cell proliferation and differentiation during SG development [134]. In pSS, studies have shown alterations in the expression levels of key components of this pathway. For instance, Wnt1 and Wnt3a expression levels were found to be elevated in the SG of pSS patients, while inhibitors of the pathway such as Dickkopf-related protein (DKK)-1 and sclerostin exhibited decreased levels in the serum [135]. Additionally, genetic polymorphism studies have identified several risk genes of pSS within the canonical Wnt/β-catenin pathway, including LRP5, FRZB, and ADIPOQ [136]. Adiponectin (ADIPOQ), in particular, acts as a regulator of the Wnt/β-catenin pathway and has been associated with anti-inflammatory effects, potentially through the induction of interleukin (IL)-10 secretion [137]. Notably, SG epithelial cells from pSS patients have shown increased expression and secretion of ADIPOQ compared to healthy subjects [138].
Similarly, the Hippo signaling pathway, known for its role in regulating organ size, cell proliferation, and differentiation, is also involved in SG development [139]. In pSS, dysregulation of this pathway leads to a shift in its effects from cell maintenance to destruction. Rather than interacting with E-cadherin to maintain cell polarity and junctional integrity, the downstream effectors such as TAZ have been demonstrated to localize in the nucleus and act as transcriptional factors due to the inhibition of the upstream kinase Lats2 [140]. This mislocalization results in the accumulation of ECM components such as fibronectin and connective tissue growth factor, potentially contributing to ECM remodeling and tissue fibrosis. Importantly, the structural defect caused by Hippo signaling dysfunction has been linked to hypo-salivation, independent of lymphocytic infiltration.
In summary, both the Wnt and Hippo signaling pathways play significant roles in SG development and are dysregulated in pSS, leading to pathological changes such as inflammation and tissue fibrosis.
Homeostasis disruption
The perturbations of cellular homeostasis can lead to cellular dysfunction, phenotypic alterations, cellular senescence, and even cell death, which may be important factors in the diminished biological viability and heightened immune response observed in SGECs (see Fig. 3).
The apoptosis of SGECs
Traditionally, impaired SG function in pSS has been attributed to epithelial apoptosis. Existing research suggests that apoptosis of SGECs in pSS is mediated by a multitude of mechanisms, including Fas-mediated pathways [141,142,143], organellar dysfunction [133, 144,145,146,147], CD8+T lymphocyte [148], B lymphocytes and autoantibodies [149,150,151], SSA/Ro52 autoantigen [152, 153], cytokines [154,155,156], TLRs signaling [157,158,159], STAT3 signaling [160, 161], and other pathways [162,163,164,165,166,167].
According to the conventional viewpoint, pSS patients with low salivary flow are expected to have minimal functional salivary tissue. However, investigations have shown a low frequency of apoptosis in SGECs from pSS patients, with no clear association between apoptosis incidence and foci score [168]. Similar findings have been replicated in animal models [169]. Additionally, a genome-wide association study revealed significant upregulation of anti-apoptosis genes in SGECs of pSS patients [170].
The hypothesis that epithelial apoptosis predominantly causes glandular damage is not entirely consistent with current research findings. It is more plausible that while epithelial cell apoptosis occurs in pSS, it alone may not fully account for the marked reduction in salivary secretion.
The endoplasmic stress in SGECs
ER serves crucial functions especially in regulating protein homeostasis by overseeing various processes including protein biogenesis, folding, assembly, transport and degradation. Excessive protein secretion or perturbed ER protein folding can lead to aggregation of unfolded or misfolded proteins within the ER lumen, which is termed as ER stress, a condition that activates the unfolded protein response (UPRER). UPRER is sensed by three ER transmembrane stress receptors: inositol-requiring enzyme 1α (IRE1α), activating transcription factor 6α (ATF6α) and PKR-like endoplasmic reticulum kinase [171]. Activation of UPRER aims to reduce translation to alleviate the burden on nascent protein folding, degrading unfolded proteins, and increasing chaperone expression to facilitate protein folding.
Cells with high secretory requirements, such as acinar cells of the SGs, are particularly susceptible to environmental factors that impose ER stress. Exposure to pro-inflammatory stimulant such as reactive oxygen species (ROS), cytokines and DAMPs can elicit UPRER, while alterations in UPRER signaling can reciprocally initiate inflammatory pathways [172].
Studies have shown that the SGs of pSS patients experience persistent ER stress. Growth arrest and DNA damage inducible protein 153, a canonical marker of ER stress response, displayed elevated expression in the ductal epithelium of NOD mice and pSS patients [173]. Increased ATF6α pathway and ER-associated protein degradation (ERAD) activities were observed in LSGs from pSS patients, potentially contributing to preventing apoptosis [174]. Additionally, IRE1α/XBP-1 pathway, another branch of UPRER, has been found impaired in LSGs of pSS patients, with heightened methylation levels of their promoters [175]. ERdj5, critical in ERAD for processing misfolded proteins, was found upregulated in the LSGs of pSS patients, while ERdj5−/− mice exhibited SS-like phenotypes, including decreased SG function, periductal inflammation in SGs and elevated serum autoantibodies levels [176]. Moreover, abnormalities in protein secretion can induce ER stress, as evidenced by the overexpression and aggregation of MUC1 in the ER of acinar epithelial cells from pSS patients, along with its co-precipitation with glucose-regulated protein 78 (GRP78) [177]. A recent study found that the GRP78-ATF6-CHOP signaling was hyperactive in LSGs of pSS patients, and suppression of this pathway increased salivation in a murine model [147], implicating ER stress in SG lesions in pSS.
The mitochondrial dysfunction of SGECs
Mitochondria, essential in energy production, apoptosis, Ca2+ homeostasis, and innate immunity, are the major source of ROS in the process of generating energy through oxidative phosphorylation [178]. When ROS production exceeds the capacity of antioxidant protection, oxidative stress (OS) takes place.
Several studies have implicated OS in the injury of SGs in pSS patients. Two OS markers, 8-hydroxy-2ʹ-deoxyguanosine (8-OHdG) and hexanoyl-lysine (HEL), were proved to be increased in the saliva of pSS patients, whereas such changes were absent in individuals with SG dysfunction unrelated to pSS or in healthy controls. Moreover, the mitochondrial glutamic-oxaloacetic transaminase level in the saliva of pSS patients was remarkably correlated with the 8-OHdG and HEL levels [179]. A knockout mouse with a deletion of superoxide dismutase related gene was reported to have reduced salivary secretion without obvious inflammation of the SGs [180], suggesting a potential role of OS in salivary secretion disorders.
Dysfunctional mitochondria not only generate high levels of ROS, but also appear to serve as important inflammatory triggers. Considering that mitochondria are believed to have originated from symbiotic aerobic prokaryotic bacteria, various components and metabolic byproducts of mitochondria can function as DAMPs, thereby promoting inflammation upon release into the cytoplasm or extracellular milieu [181]. These mitochondrial DAMPs can activate several signaling pathways, including the cyclic GMP-AMP synthase and stimulator of IFN response cGAMP interactor 1 (cGAS-STING1) signal pathway, inflammasome signal pathway, and inflammatory pathways mediated by pattern recognition receptors [181]. These mechanisms may contribute to the intrinsic activation observed in SGECs of pSS patients [182, 183].
Evidence of structural mitochondrial damage in epithelial cells derived from pSS patients has been documented. Transmission electron microscopy revealed mitochondrial membrane disruption, cristae loss and disorganization, and mitochondrial matrix swelling in SGECs of pSS patients [184,185,186]. Given the pivotal role mitochondria play in various cellular processes, abnormalities in mitochondrial structure and function inevitably result in impaired epithelial function.
The lysosome and autophagy dysfunction of SGECs
Lysosomes are membrane-bound cellular organelles containing digestive enzymes that have been found to participate in various cellular processes, including secretion, biomolecule degradation, immune response, cell death, etc. Through autophagy, a self-catabolic process, lysosomes dispose of intracellular contents [187].
Lysosomal abnormalities within SGECs can contribute to the development of pSS through several mechanisms. The LAMP3 have been found expressed higher in SGECs of pSS patients in comparison to control groups. This overexpression of LAMP3 was thought to be related with the release of autoantigens including components of SSA (TRIM21), SSB (La), and α-fodrin protein via extracellular vesicles, independently of apoptosis mechanisms [146]. Animal experiments have demonstrated that altered lysosomal function, via LAMP3 overexpression in SGECs, was involved in the salivary dysfunction and autoimmune activation [133]. Lysosomal damage often results in lysosomal membrane permeabilization (LMP) [188], leading to the inappropriate release of cathepsin into the cytoplasm, which in turn triggers caspase-dependent apoptosis of SGECs [189]. Dysfunctional lysosomes may exacerbate the degradation of membrane proteins crucial for salivation, such as NKCC1 and AQP5 [190]. Additionally, increased lysosomal exocytosis leads to the release of DAMPs, which activate immune cells via TLRs receptors [132].
Autophagy is a cellular degradation process that eliminates futile or impaired components through lysosome-based mechanisms. Autophagy is important in maintaining cellular homeostasis and is conducive to cell survival. In one study involving human SGEC lines, ER stress inducers were able to elicit autophagy, which subsequently inhibited apoptosis following ER stress in SGECs [145]. Notably, autophagy-deficient mice exhibited an SS-like phenotype characterized by immune cell infiltration in exocrine tissues, and impaired GATE16-mediated exocytosis in SG acinar cells has been found [191]. The aforementioned studies underscore the protective role of autophagy in SGECs during glandular damage. A recent study, however, discovered that autophagy in SGECs of pSS patients was correlated with histologic disease severity. Stimulation of human SGEC lines with peripheral mononuclear cells and serum from pSS patients induced autophagy and release of adhesion molecules, which could be reversed by autophagy inhibitor [192]. This suggests that autophagy may play a role in the intrinsic activation of SGECs.
Premature senescence of stem/progenitor cells
The preservation of SG hinges notably on the delicate balance between cell death and proliferation modulated by resident mature stem/progenitor cells [193]. Stem cells possess the capability for unlimited self-renewal, giving rise to progenitor cells that subsequently lose this capacity. Their distinction between these cell types, however, remains somewhat ambiguous, leading to the common usage of the term “stem/progenitor cell” [194, 195]. In the context of normal SG homeostasis, salivary gland progenitor cells (SGPCs) proliferate and differentiate into new epithelial cells, replenishing those lost due to damage or senescence [196,197,198].
In pSS, the premature senescence of stem/progenitor cells within SGs has garnered increasing attention. One study presented evidence of premature aging in salivary gland stem cells (SGSCs) among pSS patients [199], wherein both the quantity and self-renewal capacity of SGSCs were significantly diminished compared to healthy controls. This premature senescence phenomenon manifests at various stages of the disease progression. In the early stage of pSS, prior to lymphocyte focus formation, an upregulation of beta-galactosidase-like gene GLB1L2, considered a hallmark of cellular aging, was observed. In later phases, STELA analysis showed a sharp reduction in the telomere length in SGSCs from pSS samples, indicative of extensive replicative history [199].
Beyond SGSCs, senescence in SGPCs is also demonstrated in early stages of pSS. As well established, cell senescence is marked by characteristic expression of p16, a suppressor of cell division kinase 4 [200]. Compared to healthy controls, SGs of pSS patients generally exhibit a higher prevalence of p16+ cells within both the epithelium and the SGPC niche [201]. This phenomenon is associated with defective SG secretory function, but does not correlate with systematic disease activity. Moreover, individuals exhibiting signs suggestive of potential development into pSS, albeit not meeting the ACR-EULAR criteria, exhibit an elevated number of p16+ cells within epithelium and SGPC niche compared to non-SS sicca patients, whereas at levels lower than observed in confirmed pSS patients. This denotes an early and continuous process in the pathogenesis of pSS [201].
Intriguingly, senescent cells can develop a senescence-associated secretory phenotype, characterized by the secretion of various growth modulators, angiogenic factors, pro-inflammatory cytokines, MMPs, etc. [202]. The existence of this phenotype within SGs of pSS patients, and its impact on stem/progenitor cells, warrants further investigation.
Conclusions and future prospect
Epithelial lesions in autoimmune epithelitis, including reduced salivation observed in pSS, are complicated phenomena that cannot be solely attributed to lymphocytic infiltration. Alterations in SGECs such as viral infection, epigenetic dysregulation, structural disorder, secretory dysfunction, signaling aberrations, and homeostasis disruption all have a role in the occurrence and development of pSS (see Table 1). It is noteworthy that some of these alterations can occur independently of or in absence of lymphocytic infiltration, and may even serve as upstream factors for immuno-inflammatory responses. Given the limited efficacy of current immunological treatments, we reckon these findings significant for re-examining the pathogenesis of pSS and developing interventions targeting SGECs in the early stages of the disease.
Several non-immunological strategies show promising prospects for ameliorating or reversing epithelial lesions and treating xerostomia in pSS. For example, muscarinic agonists, such as pilocarpine [203], can effectively enhance secretion by promoting calcium-induced trafficking of AQP to the apical membrane. Low-intensity pulsed ultrasounds [204] and gene delivery of hAqp1 [205] have also demonstrated the ability to elevate AQP expression. Bone marrow therapy and spleen cell therapy [206] can replenish stem cells to restore damaged epithelial cells. Furthermore, potential intervention targets include ZO-1 and claudins, which regulate TJ structure; MMPs, which influence BM and ECM; EGF, which promotes epidermal healing and cross-influences neurotransmission; SMADs and BMP6, which participate in TGF-β signaling and fibrosis; and UPRER signaling, which induce apoptosis. However, a more comprehensive understanding of the pathological mechanisms is necessary for successful translation into clinical therapies.
Availability of data and materials
Not applicable.
Abbreviations
- pSS:
-
Primary Sjögren’s syndrome
- SG:
-
Salivary gland
- PBC:
-
Primary biliary cholangitis
- SGEC:
-
Salivary gland epithelial cell
- AQP:
-
Aquaporins
- BM:
-
Basement membrane
- ECM:
-
Extracellular matrix
- TJ:
-
Tight junction
- GJ:
-
Gap junctions
- AJ:
-
Adherens junctions
- HD:
-
Hemidesmosomes
- ACh:
-
Acetylcholine
- PLC:
-
Phospholipase C
- PIP2:
-
Phosphatidylinositol 4,5-bisphosphate
- IP3(R):
-
1,4,5-Triphosphate (receptor)
- [Ca2+]i:
-
Intracellular Ca2+ concentration
- ER:
-
Endoplasmic reticulum
- SOCE:
-
Store-operated calcium entry
- CRAC:
-
Ca2+ release-activated Ca2+
- EBV:
-
Epstein–Barr virus
- HTLV-1:
-
Human T-cell leukemia virus type 1
- TLR:
-
Toll-like receptor
- TET2:
-
Ten-eleven translocation 2
- Wnt:
-
Wingless
- P-ezrin:
-
Thr-567 Phosphorylated ezrin
- LSG:
-
Labial salivary glands
- MMP:
-
Matrix metalloproteinase
- DAMP:
-
Damage associated molecular patterns
- M3R:
-
M3 Muscarinic ACh receptor
- IFN:
-
Interferon
- RyR:
-
Ryanodine receptor
- cADP:
-
Cyclic adenosine diphosphate
- cGMP:
-
Cyclic guanosine monophosphate
- NO:
-
Nitric oxide
- STX:
-
Syntaxin
- EGF(R):
-
Epidermal growth factor (receptor)
- ERK:
-
Extracellular signal-regulated kinase
- TGF:
-
Transforming growth factor
- EMT:
-
Epithelial–mesenchymal transition
- BMP:
-
Bone morphogenetic protein
- LAMP:
-
Lysosome-associated membrane protein
- LRP:
-
Lipoprotein receptor-related protein
- FRZB:
-
Frizzled-related protein
- DKK:
-
Dickkopf-related protein
- ADIPOQ:
-
Adiponectin
- IL:
-
Interleukin
- UPR:
-
Unfolded protein response
- IRE:
-
Inositol-requiring enzyme
- ATF:
-
Activating transcription factor
- ROS:
-
Reactive oxygen species
- GADD:
-
Growth arrest and DNA damage inducible protein
- ERAD:
-
ER-associated protein degradation
- GRP:
-
Glucose-regulated protein
- OS:
-
Oxidative stress
- 8-OHdG:
-
8-Hydroxy-2ʹ-deoxyguanosine
- HEL:
-
Hexanoyl-lysine
- LMP:
-
Lysosomal membrane permeabilization
- SGPC:
-
Salivary gland progenitor cell
- SGSC:
-
Salivary gland stem cells
References
Mariette X, Criswell LA. Primary Sjögren’s Syndrome. N Engl J Med. 2018;378(10):931–9. https://doi.org/10.1056/NEJMcp1702514.
Zhou Z, Liu H, Yang Y, Zhou J, Zhao L, Chen H, et al. The five major autoimmune diseases increase the risk of cancer: epidemiological data from a large-scale cohort study in China. Cancer Commun (Lond). 2022;42(5):435–46. https://doi.org/10.1002/cac2.12283.
Maleki-Fischbach M, Kastsianok L, Koslow M, Chan ED. Manifestations and management of Sjögren’s disease. Arthritis Res Ther. 2024;26(1):43. https://doi.org/10.1186/s13075-024-03262-4.
McCoy SS, Woodham M, Bunya VY, Saldanha IJ, Akpek EK, Makara MA, et al. A comprehensive overview of living with Sjögren’s: results of a National Sjögren’s Foundation survey. Clin Rheumatol. 2022;41(7):2071–8. https://doi.org/10.1007/s10067-022-06119-w.
Martínez-Ceballos MA, Aguilera N, Garzón-González KC, Cajamarca-Baron J, Alzate-Granados JP, Rojas-Villarraga A. Unstimulated whole salivary flow in Sjögren’s Syndrome: systematic literature review and meta-analysis. Adv Rheumatol. 2021;61(1):8. https://doi.org/10.1186/s42358-020-00158-0.
Azuma N, Katada Y, Sano H. Deterioration in saliva quality in patients with Sjögren’s syndrome: impact of decrease in salivary epidermal growth factor on the severity of intraoral manifestations. Inflamm Regen. 2018;38:6. https://doi.org/10.1186/s41232-018-0062-0.
Serrano J, López-Pintor RM, Fernández-Castro M, Ramírez L, Sanz M, Casañas E, et al. Oral lesions in patients with primary Sjögren’s syndrome. A case-control cross-sectional study. Med Oral Patol Oral Cir Bucal. 2020;25(1):e137–43. https://doi.org/10.4317/medoral.23254.
Bodewes ILA, Gottenberg JE, van Helden-Meeuwsen CG, Mariette X, Versnel MA. Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren’s syndrome in the JOQUER randomized trial. Rheumatology (Oxford). 2020;59(1):107–11. https://doi.org/10.1093/rheumatology/kez242.
Fang W, Qingqing Z, Qihui L, Bing Z, Xinyue H, Jie X. Safety and efficacy of oral hydroxychloroquine in the treatment of ophthalmic disease associated with Sjögren’s syndrome. Altern Ther Health Med. 2023;29(8):656–62.
Wang X, Zhang T, Guo Z, Pu J, Riaz F, Feng R, et al. The efficiency of hydroxychloroquine for the treatment of primary Sjögren’s syndrome: a systematic review and meta-analysis. Front Pharmacol. 2021;12: 693796. https://doi.org/10.3389/fphar.2021.693796.
Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM. Methotrexate in primary Sjögren’s syndrome. Clin Exp Rheumatol. 1996;14(5):555–8.
Drosos AA, Skopouli FN, Costopoulos JS, Papadimitriou CS, Moutsopoulos HM. Cyclosporin A (CyA) in primary Sjögren’s syndrome: a double blind study. Ann Rheum Dis. 1986;45(9):732–5. https://doi.org/10.1136/ard.45.9.732.
van Woerkom JM, Kruize AA, Geenen R, van Roon EN, Goldschmeding R, Verstappen SM, et al. Safety and efficacy of leflunomide in primary Sjögren’s syndrome: a phase II pilot study. Ann Rheum Dis. 2007;66(8):1026–32. https://doi.org/10.1136/ard.2006.060905.
Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjögren’s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren’s Syndrome (TRIPSS). Arthritis Rheum. 2004;50(4):1270–6. https://doi.org/10.1002/art.20146.
Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, et al. Etanercept in Sjögren’s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50(7):2240–5. https://doi.org/10.1002/art.20299.
Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjögren’ syndrome: an open-label phase II study. Arthritis Rheum. 2005;52(9):2740–50. https://doi.org/10.1002/art.21260.
Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, et al. Improvement of Sjögren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007;57(2):310–7. https://doi.org/10.1002/art.22536.
St Clair EW, Levesque MC, Prak ET, Vivino FB, Alappatt CJ, Spychala ME, et al. Rituximab therapy for primary Sjögren’s syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum. 2013;65(4):1097–106. https://doi.org/10.1002/art.37850.
Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160(4):233–42. https://doi.org/10.7326/m13-1085.
Bowman SJ, Everett CC, O’Dwyer JL, Emery P, Pitzalis C, Ng WF, et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren’s syndrome. Arthritis Rheumatol. 2017;69(7):1440–50. https://doi.org/10.1002/art.40093.
Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, et al. Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2015;74(3):526–31. https://doi.org/10.1136/annrheumdis-2013-203991.
Pontarini E, Fabris M, Quartuccio L, Cappeletti M, Calcaterra F, Roberto A, et al. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren’s syndrome. Rheumatology (Oxford). 2015;54(8):1429–34. https://doi.org/10.1093/rheumatology/kev005.
De Vita S, Quartuccio L, Seror R, Salvin S, Ravaud P, Fabris M, et al. Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study. Rheumatology (Oxford). 2015;54(12):2249–56. https://doi.org/10.1093/rheumatology/kev257.
Baer AN, Gottenberg JE, St Clair EW, Sumida T, Takeuchi T, Seror R, et al. Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial. Ann Rheum Dis. 2021;80(3):339–48. https://doi.org/10.1136/annrheumdis-2020-218599.
de Wolff L, van Nimwegen JF, Mossel E, van Zuiden GS, Stel AJ, Majoor KI, et al. Long-term abatacept treatment for 48 weeks in patients with primary Sjögren’s syndrome: the open-label extension phase of the ASAP-III trial. Semin Arthritis Rheum. 2022;53: 151955. https://doi.org/10.1016/j.semarthrit.2022.151955.
Both T, Dalm VA, van Hagen PM, van Daele PL. Reviewing primary Sjögren’s syndrome: beyond the dryness—from pathophysiology to diagnosis and treatment. Int J Med Sci. 2017;14(3):191–200. https://doi.org/10.7150/ijms.17718.
Sebastian A, Woytala P, Madej M, Proc K, Czesak-Woytala K, Sebastian M, et al. Is it possible to not perform salivary gland biopsy in targeted patients according to unstimulated salivary flow results in patients with suspected Sjögren’s syndrome? Rheumatol Int. 2021;41(6):1125–31. https://doi.org/10.1007/s00296-021-04840-4.
Gannot G, Lancaster HE, Fox PC. Clinical course of primary Sjögren’s syndrome: salivary, oral, and serologic aspects. J Rheumatol. 2000;27(8):1905–9.
Theander E, Andersson SI, Manthorpe R, Jacobsson LT. Proposed core set of outcome measures in patients with primary Sjögren’s syndrome: 5 year follow up. J Rheumatol. 2005;32(8):1495–502.
Jonsson MV, Delaleu N, Brokstad KA, Berggreen E, Skarstein K. Impaired salivary gland function in NOD mice: association with changes in cytokine profile but not with histopathologic changes in the salivary gland. Arthritis Rheum. 2006;54(7):2300–5. https://doi.org/10.1002/art.21945.
Chatzis LG, Koulouri V, Baldini C, Pezoulas VC, Voulgari PV, Skopouli FN, et al. Clinical and laboratory findings of primary Sjögren’s syndrome patients without sicca symptoms. Clin Exp Rheumatol. 2022. https://doi.org/10.55563/clinexprheumatol/gqvyus.
Liao R, Yang HT, Li H, Liu LX, Li K, Li JJ, et al. Recent advances of salivary gland biopsy in Sjögren’s syndrome. Front Med (Lausanne). 2021;8: 792593. https://doi.org/10.3389/fmed.2021.792593.
Selmi C, Gershwin ME. Chronic autoimmune epithelitis in Sjögren’s syndrome and primary biliary cholangitis: a comprehensive review. Rheumatol Ther. 2017;4(2):263–79. https://doi.org/10.1007/s40744-017-0074-2.
Arvaniti P, Zachou K, Lyberopoulou A, Gatselis NK, Brooks WH, Dalekos GN, et al. Epigenetic modifications in generalized autoimmune epithelitis: Sjögren’s Syndrome and primary biliary cholangitis. Epigenomes. 2019. https://doi.org/10.3390/epigenomes3030015.
Gao J, Qiao L, Wang B. Primary biliary cirrhosis is a generalized autoimmune epithelitis. Int J Mol Sci. 2015;16(3):6432–46. https://doi.org/10.3390/ijms16036432.
Desvaux E, Pers JO. Autoimmune epithelitis in primary Sjögren’s syndrome. Joint Bone Spine. 2023;90(2): 105479. https://doi.org/10.1016/j.jbspin.2022.105479.
Shang YF, Shen YY, Zhang MC, Lv MC, Wang TY, Chen XQ, et al. Progress in salivary glands: endocrine glands with immune functions. Front Endocrinol (Lausanne). 2023;14:1061235. https://doi.org/10.3389/fendo.2023.1061235.
Proctor GB. The physiology of salivary secretion. Periodontol 2000. 2016;70(1):11–25. https://doi.org/10.1111/prd.12116.
Cote LE, Feldman JL. Won’t you be my neighbor: how epithelial cells connect together to build global tissue polarity. Front Cell Dev Biol. 2022;10: 887107. https://doi.org/10.3389/fcell.2022.887107.
Samiei M, Ahmadian E, Eftekhari A, Eghbal MA, Rezaie F, Vinken M. Cell junctions and oral health. Excli J. 2019;18:317–30. https://doi.org/10.17179/excli2019-1370.
Otani T, Furuse M. Tight junction structure and function revisited. Trends Cell Biol. 2020;30(10):805–17. https://doi.org/10.1016/j.tcb.2020.08.004.
Proctor GB, Carpenter GH. Salivary secretion: mechanism and neural regulation. Monogr Oral Sci. 2014;24:14–29. https://doi.org/10.1159/000358781.
Melvin JE, Yule D, Shuttleworth T, Begenisich T. Regulation of fluid and electrolyte secretion in salivary gland acinar cells. Annu Rev Physiol. 2005;67:445–69. https://doi.org/10.1146/annurev.physiol.67.041703.084745.
Ambudkar IS. Ca2+ signaling and regulation of fluid secretion in salivary gland acinar cells. Cell Calcium. 2014;55(6):297–305. https://doi.org/10.1016/j.ceca.2014.02.009.
Ambudkar IS. Dissection of calcium signaling events in exocrine secretion. Neurochem Res. 2011;36(7):1212–21. https://doi.org/10.1007/s11064-011-0465-7.
Hong JH, Park S, Shcheynikov N, Muallem S. Mechanism and synergism in epithelial fluid and electrolyte secretion. Pflugers Arch. 2014;466(8):1487–99. https://doi.org/10.1007/s00424-013-1390-1.
Roussa E. Channels and transporters in salivary glands. Cell Tissue Res. 2011;343(2):263–87. https://doi.org/10.1007/s00441-010-1089-y.
Errachid A, Nohawica M, Wyganowska-Swiatkowska M. A comprehensive review of the influence of Epigallocatechin gallate on Sjögren’s syndrome associated molecular regulators of exocytosis (Review). Biomed Rep. 2021;15(5):95. https://doi.org/10.3892/br.2021.1471.
Chibly AM, Aure MH, Patel VN, Hoffman MP. Salivary gland function, development, and regeneration. Physiol Rev. 2022;102(3):1495–552. https://doi.org/10.1152/physrev.00015.2021.
Çelebioğlu HY, Lee S, Chronakis IS. Interactions of salivary mucins and saliva with food proteins: a review. Crit Rev Food Sci Nutr. 2020;60(1):64–83. https://doi.org/10.1080/10408398.2018.1512950.
Houen G, Trier NH. Epstein-Barr virus and systemic autoimmune diseases. Front Immunol. 2020;11: 587380. https://doi.org/10.3389/fimmu.2020.587380.
Iwakiri D, Zhou L, Samanta M, Matsumoto M, Ebihara T, Seya T, et al. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp Med. 2009;206(10):2091–9. https://doi.org/10.1084/jem.20081761.
Nakamura H, Shimizu T, Kawakami A. Role of viral infections in the pathogenesis of Sjögren’s syndrome: different characteristics of Epstein-Barr virus and HTLV-1. J Clin Med. 2020. https://doi.org/10.3390/jcm9051459.
Gallo A, Jang SI, Ong HL, Perez P, Tandon M, Ambudkar I, et al. Targeting the Ca(2+) sensor STIM1 by exosomal transfer of Ebv-miR-BART13-3p is associated with Sjögren’s syndrome. EBioMedicine. 2016;10:216–26. https://doi.org/10.1016/j.ebiom.2016.06.041.
Nakamura H, Takahashi Y, Yamamoto-Fukuda T, Horai Y, Nakashima Y, Arima K, et al. Direct infection of primary salivary gland epithelial cells by human T lymphotropic virus type I in patients with Sjögren’s syndrome. Arthritis Rheumatol. 2015;67(4):1096–106. https://doi.org/10.1002/art.39009.
Nakamura H, Shimizu T, Takatani A, Suematsu T, Nakamura T, Kawakami A. Initial human T-cell leukemia virus type 1 infection of the salivary gland epithelial cells requires a biofilm-like structure. Virus Res. 2019;269: 197643. https://doi.org/10.1016/j.virusres.2019.197643.
Nakamura H, Kawakami A. What is the evidence for Sjögren’s syndrome being triggered by viral infection? Subplot: infections that cause clinical features of Sjögren’s syndrome. Curr Opin Rheumatol. 2016;28(4):390–7. https://doi.org/10.1097/bor.0000000000000287.
Thabet Y, Le Dantec C, Ghedira I, Devauchelle V, Cornec D, Pers JO, et al. Epigenetic dysregulation in salivary glands from patients with primary Sjögren’s syndrome may be ascribed to infiltrating B cells. J Autoimmun. 2013;41:175–81. https://doi.org/10.1016/j.jaut.2013.02.002.
Konsta OD, Charras A, Le Dantec C, Kapsogeorgeou E, Bordron A, Brooks WH, et al. Epigenetic modifications in salivary glands from patients with Sjögren’s syndrome affect cytokeratin 19 expression. Bull Group Int Rech Sci Stomatol Odontol. 2016;53(1): e01.
Lagos C, Carvajal P, Castro I, Jara D, González S, Aguilera S, et al. Association of high 5-hydroxymethylcytosine levels with Ten Eleven Translocation 2 overexpression and inflammation in Sjögren’s syndrome patients. Clin Immunol. 2018;196:85–96. https://doi.org/10.1016/j.clim.2018.06.002.
Konsta OD, Le Dantec C, Charras A, Cornec D, Kapsogeorgou EK, Tzioufas AG, et al. Defective DNA methylation in salivary gland epithelial acini from patients with Sjögren’s syndrome is associated with SSB gene expression, anti-SSB/LA detection, and lymphocyte infiltration. J Autoimmun. 2016;68:30–8. https://doi.org/10.1016/j.jaut.2015.12.002.
Charras A, Konsta OD, Le Dantec C, Bagacean C, Kapsogeorgou EK, Tzioufas AG, et al. Cell-specific epigenome-wide DNA methylation profile in long-term cultured minor salivary gland epithelial cells from patients with Sjögren’s syndrome. Ann Rheum Dis. 2017;76(3):625–8. https://doi.org/10.1136/annrheumdis-2016-210167.
Kapsogeorgou EK, Gourzi VC, Manoussakis MN, Moutsopoulos HM, Tzioufas AG. Cellular microRNAs (miRNAs) and Sjögren’s syndrome: candidate regulators of autoimmune response and autoantigen expression. J Autoimmun. 2011;37(2):129–35. https://doi.org/10.1016/j.jaut.2011.05.003.
Gourzi VC, Kapsogeorgou EK, Kyriakidis NC, Tzioufas AG. Study of microRNAs (miRNAs) that are predicted to target the autoantigens Ro/SSA and La/SSB in primary Sjögren’s Syndrome. Clin Exp Immunol. 2015;182(1):14–22. https://doi.org/10.1111/cei.12664.
Pauley KM, Stewart CM, Gauna AE, Dupre LC, Kuklani R, Chan AL, et al. Altered miR-146a expression in Sjögren’s syndrome and its functional role in innate immunity. Eur J Immunol. 2011;41(7):2029–39. https://doi.org/10.1002/eji.201040757.
Gauna AE, Park YJ, Nayar G, Onate M, Jin JO, Stewart CM, et al. Dysregulated co-stimulatory molecule expression in a Sjögren’s syndrome mouse model with potential implications by microRNA-146a. Mol Immunol. 2015;68(2):606–16. https://doi.org/10.1016/j.molimm.2015.09.027.
Jang SI, Tandon M, Teos L, Zheng C, Warner BM, Alevizos I. Dual function of miR-1248 links interferon induction and calcium signaling defects in Sjögren’s syndrome. EBioMedicine. 2019;48:526–38. https://doi.org/10.1016/j.ebiom.2019.09.010.
Golder W, Stiller M. Distribution pattern of Sjögren’s syndrome: a sialographical study. Z Rheumatol. 2014;73(10):928–33. https://doi.org/10.1007/s00393-014-1372-5.
van Ginkel MS, Glaudemans A, van der Vegt B, Mossel E, Kroese FGM, Bootsma H, et al. Imaging in primary Sjögren’s syndrome. J Clin Med. 2020. https://doi.org/10.3390/jcm9082492.
Cho A, Lee YR, Jeon YT, Chang SH, Park YM, Ahn SJ, et al. Correlations of MR sialographic gradings with the clinical measures of Sjögren’s syndrome. Laryngoscope. 2022. https://doi.org/10.1002/lary.30150.
Goicovich E, Molina C, Pérez P, Aguilera S, Fernández J, Olea N, et al. Enhanced degradation of proteins of the basal lamina and stroma by matrix metalloproteinases from the salivary glands of Sjögren’s syndrome patients: correlation with reduced structural integrity of acini and ducts. Arthritis Rheum. 2003;48(9):2573–84. https://doi.org/10.1002/art.11178.
Pérez P, Aguilera S, Olea N, Alliende C, Molina C, Brito M, et al. Aberrant localization of ezrin correlates with salivary acini disorganization in Sjogren’s Syndrome. Rheumatology (Oxford). 2010;49(5):915–23. https://doi.org/10.1093/rheumatology/keq033.
Chivasso C, Hagströmer CJ, Rose KL, Lhotellerie F, Leblanc L, Wang Z, et al. Ezrin is a novel protein partner of aquaporin-5 in human salivary glands and shows altered expression and cellular localization in Sjögren’s syndrome. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22179213.
Ewert P, Aguilera S, Alliende C, Kwon YJ, Albornoz A, Molina C, et al. Disruption of tight junction structure in salivary glands from Sjögren’s syndrome patients is linked to proinflammatory cytokine exposure. Arthritis Rheum. 2010;62(5):1280–9. https://doi.org/10.1002/art.27362.
Peck AB, Saylor BT, Nguyen L, Sharma A, She JX, Nguyen CQ, et al. Gene expression profiling of early-phase Sjögren’s syndrome in C57BL/6.NOD-Aec1Aec2 mice identifies focal adhesion maturation associated with infiltrating leukocytes. Invest Ophthalmol Vis Sci. 2011;52(8):5647–55. https://doi.org/10.1167/iovs.11-7652.
Barrera MJ, Bahamondes V, Sepúlveda D, Quest AF, Castro I, Cortés J, et al. Sjögren’s syndrome and the epithelial target: a comprehensive review. J Autoimmun. 2013;42:7–18. https://doi.org/10.1016/j.jaut.2013.02.001.
Molina C, Alliende C, Aguilera S, Kwon YJ, Leyton L, Martínez B, et al. Basal lamina disorganisation of the acini and ducts of labial salivary glands from patients with Sjogren’s syndrome: association with mononuclear cell infiltration. Ann Rheum Dis. 2006;65(2):178–83. https://doi.org/10.1136/ard.2004.033837.
Sisto M, D’Amore M, Lofrumento DD, Scagliusi P, D’Amore S, Mitolo V, et al. Fibulin-6 expression and anoikis in human salivary gland epithelial cells: implications in Sjogren’s syndrome. Int Immunol. 2009;21(3):303–11. https://doi.org/10.1093/intimm/dxp001.
Sequeira SJ, Larsen M, DeVine T. Extracellular matrix and growth factors in salivary gland development. Front Oral Biol. 2010;14:48–77. https://doi.org/10.1159/000313707.
McArthur CP, Daniels PJ, Kragel P, Howard PF, Julian L. Sjögren’s syndrome salivary gland immunopathology: increased laminin expression precedes lymphocytic infiltration. J Autoimmun. 1997;10(1):59–65. https://doi.org/10.1006/jaut.1996.0109.
Kwon YJ, Pérez P, Aguilera S, Molina C, Leyton L, Alliende C, et al. Involvement of specific laminins and nidogens in the active remodeling of the basal lamina of labial salivary glands from patients with Sjögren’s syndrome. Arthritis Rheum. 2006;54(11):3465–75. https://doi.org/10.1002/art.22177.
Laine M, Virtanen I, Porola P, Rotar Z, Rozman B, Poduval P, et al. Acinar epithelial cell laminin-receptors in labial salivary glands in Sjögren’s syndrome. Clin Exp Rheumatol. 2008;26(5):807–13.
Laine M, Virtanen I, Salo T, Konttinen YT. Segment-specific but pathologic laminin isoform profiles in human labial salivary glands of patients with Sjogren’s syndrome. Arthritis Rheum. 2004;50(12):3968–73. https://doi.org/10.1002/art.20730.
Pérez P, Kwon YJ, Alliende C, Leyton L, Aguilera S, Molina C, et al. Increased acinar damage of salivary glands of patients with Sjögren’s syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios. Arthritis Rheum. 2005;52(9):2751–60. https://doi.org/10.1002/art.21265.
Walko G, Castañón MJ, Wiche G. Molecular architecture and function of the hemidesmosome. Cell Tissue Res. 2015;360(2):363–78. https://doi.org/10.1007/s00441-014-2061-z.
González S, Aguilera S, Alliende C, Urzúa U, Quest AF, Herrera L, et al. Alterations in type I hemidesmosome components suggestive of epigenetic control in the salivary glands of patients with Sjögren’s syndrome. Arthritis Rheum. 2011;63(4):1106–15. https://doi.org/10.1002/art.30212.
Velozo J, Aguilera S, Alliende C, Ewert P, Molina C, Pérez P, et al. Severe alterations in expression and localisation of {alpha}6{beta}4 integrin in salivary gland acini from patients with Sjogren syndrome. Ann Rheum Dis. 2009;68(6):991–6. https://doi.org/10.1136/ard.2008.089607.
Pérez P, Goicovich E, Alliende C, Aguilera S, Leyton C, Molina C, et al. Differential expression of matrix metalloproteinases in labial salivary glands of patients with primary Sjögren’s syndrome. Arthritis Rheum. 2000;43(12):2807–17. https://doi.org/10.1002/1529-0131(200012)43:12%3c2807::Aid-anr22%3e3.0.Co;2-m.
Manninen A. Epithelial polarity–generating and integrating signals from the ECM with integrins. Exp Cell Res. 2015;334(2):337–49. https://doi.org/10.1016/j.yexcr.2015.01.003.
Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acuña JM, Perez-Romero BA, Guerrero-Rodriguez JF, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21249739.
Konttinen YT, Halinen S, Hanemaaijer R, Sorsa T, Hietanen J, Ceponis A, et al. Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjögren’s syndrome. Matrix Biol. 1998;17(5):335–47. https://doi.org/10.1016/s0945-053x(98)90086-5.
Kiripolsky J, Kasperek EM, Zhu C, Li QZ, Wang J, Yu G, et al. Immune-intrinsic Myd88 Directs the production of antibodies with specificity for extracellular matrix components in primary Sjögren’s syndrome. Front Immunol. 2021;12: 692216. https://doi.org/10.3389/fimmu.2021.692216.
Zoukhri D, Hodges RR, Dartt DA. Lacrimal gland innervation is not altered with the onset and progression of disease in a murine model of Sjögren’s syndrome. Clin Immunol Immunopathol. 1998;89(2):126–33. https://doi.org/10.1006/clin.1998.4597.
Pedersen AM, Dissing S, Fahrenkrug J, Hannibal J, Reibel J, Nauntofte B. Innervation pattern and Ca2+ signalling in labial salivary glands of healthy individuals and patients with primary Sjögren’s syndrome (pSS). J Oral Pathol Med. 2000;29(3):97–109. https://doi.org/10.1034/j.1600-0714.2000.290301.x.
Zoukhri D, Kublin CL. Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjögren’s syndrome. Invest Ophthalmol Vis Sci. 2001;42(5):925–32.
Dawson LJ, Christmas SE, Smith PM. An investigation of interactions between the immune system and stimulus-secretion coupling in mouse submandibular acinar cells. A possible mechanism to account for reduced salivary flow rates associated with the onset of Sjögren’s syndrome. Rheumatology (Oxford). 2000;39(11):1226–33. https://doi.org/10.1093/rheumatology/39.11.1226.
Beroukas D, Goodfellow R, Hiscock J, Jonsson R, Gordon TP, Waterman SA. Up-regulation of M3-muscarinic receptors in labial salivary gland acini in primary Sjögren’s syndrome. Lab Invest. 2002;82(2):203–10. https://doi.org/10.1038/labinvest.3780412.
Reina S, Orman B, Anaya JM, Sterin-Borda L, Borda E. Cholinoreceptor autoantibodies in Sjögren syndrome. J Dent Res. 2007;86(9):832–6. https://doi.org/10.1177/154405910708600905.
Bacman S, Sterin-Borda L, Camusso JJ, Arana R, Hubscher O, Borda E. Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjögren’s syndrome. Clin Exp Immunol. 1996;104(3):454–9. https://doi.org/10.1046/j.1365-2249.1996.42748.x.
Tsuboi H, Matsumoto I, Wakamatsu E, Nakamura Y, Iizuka M, Hayashi T, et al. New epitopes and function of anti-M3 muscarinic acetylcholine receptor antibodies in patients with Sjögren’s syndrome. Clin Exp Immunol. 2010;162(1):53–61. https://doi.org/10.1111/j.1365-2249.2010.04188.x.
Appel S, Le Hellard S, Bruland O, Brun JG, Omdal R, Kristjansdottir G, et al. Potential association of muscarinic receptor 3 gene variants with primary Sjogren’s syndrome. Ann Rheum Dis. 2011;70(7):1327–9. https://doi.org/10.1136/ard.2010.138966.
Dawson LJ, Field EA, Harmer AR, Smith PM. Acetylcholine-evoked calcium mobilization and ion channel activation in human labial gland acinar cells from patients with primary Sjögren’s syndrome. Clin Exp Immunol. 2001;124(3):480–5. https://doi.org/10.1046/j.1365-2249.2001.01526.x.
Teos LY, Zhang Y, Cotrim AP, Swaim W, Won JH, Ambrus J, et al. IP3R deficit underlies loss of salivary fluid secretion in Sjögren’s Syndrome. Sci Rep. 2015;5:13953. https://doi.org/10.1038/srep13953.
Caulfield VL, Balmer C, Dawson LJ, Smith PM. A role for nitric oxide-mediated glandular hypofunction in a non-apoptotic model for Sjogren’s syndrome. Rheumatology (Oxford). 2009;48(7):727–33. https://doi.org/10.1093/rheumatology/kep100.
Galione A, White A, Willmott N, Turner M, Potter BV, Watson SP. cGMP mobilizes intracellular Ca2+ in sea urchin eggs by stimulating cyclic ADP-ribose synthesis. Nature. 1993;365(6445):456–9. https://doi.org/10.1038/365456a0.
Konttinen YT, Platts LA, Tuominen S, Eklund KK, Santavirta N, Törnwall J, et al. Role of nitric oxide in Sjögren’s syndrome. Arthritis Rheum. 1997;40(5):875–83. https://doi.org/10.1002/art.1780400515.
Cortés J, Hidalgo J, Aguilera S, Castro I, Brito M, Urra H, et al. Synaptotagmin-1 overexpression under inflammatory conditions affects secretion in salivary glands from Sjögren’s syndrome patients. J Autoimmun. 2019;97:88–99. https://doi.org/10.1016/j.jaut.2018.10.019.
D’Agostino C, Parisis D, Chivasso C, Hajiabbas M, Soyfoo MS, Delporte C. Aquaporin-5 dynamic regulation. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms24031889.
Soyfoo MS, Chivasso C, Perret J, Delporte C. Involvement of aquaporins in the pathogenesis, diagnosis and treatment of Sjögren’s syndrome. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19113392.
Yoshimura S, Nakamura H, Horai Y, Nakajima H, Shiraishi H, Hayashi T, et al. Abnormal distribution of AQP5 in labial salivary glands is associated with poor saliva secretion in patients with Sjögren’s syndrome including neuromyelitis optica complicated patients. Mod Rheumatol. 2016;26(3):384–90. https://doi.org/10.3109/14397595.2015.1083146.
Steinfeld S, Cogan E, King LS, Agre P, Kiss R, Delporte C. Abnormal distribution of aquaporin-5 water channel protein in salivary glands from Sjögren’s syndrome patients. Lab Invest. 2001;81(2):143–8. https://doi.org/10.1038/labinvest.3780221.
Konttinen YT, Tensing EK, Laine M, Porola P, Törnwall J, Hukkanen M. Abnormal distribution of aquaporin-5 in salivary glands in the NOD mouse model for Sjögren’s syndrome. J Rheumatol. 2005;32(6):1071–5.
Beroukas D, Hiscock J, Jonsson R, Waterman SA, Gordon TP. Subcellular distribution of aquaporin 5 in salivary glands in primary Sjögren’s syndrome. Lancet. 2001;358(9296):1875–6. https://doi.org/10.1016/s0140-6736(01)06900-8.
Gresz V, Horvath A, Gera I, Nielsen S, Zelles T. Immunolocalization of AQP5 in resting and stimulated normal labial glands and in Sjögren’s syndrome. Oral Dis. 2015;21(1):e114–20. https://doi.org/10.1111/odi.12239.
Castro I, Sepúlveda D, Cortés J, Quest AF, Barrera MJ, Bahamondes V, et al. Oral dryness in Sjögren’s syndrome patients. Not just a question of water. Autoimmun Rev. 2013;12(5):567–74. https://doi.org/10.1016/j.autrev.2012.10.018.
Castro I, Aguilera S, Brockhausen I, Alliende C, Quest AF, Molina C, et al. Decreased salivary sulphotransferase activity correlated with inflammation and autoimmunity parameters in Sjogren’s syndrome patients. Rheumatology (Oxford). 2012;51(3):482–90. https://doi.org/10.1093/rheumatology/ker351.
Barrera MJ, Sánchez M, Aguilera S, Alliende C, Bahamondes V, Molina C, et al. Aberrant localization of fusion receptors involved in regulated exocytosis in salivary glands of Sjögren’s syndrome patients is linked to ectopic mucin secretion. J Autoimmun. 2012;39(1–2):83–92. https://doi.org/10.1016/j.jaut.2012.01.011.
Bahamondes V, Albornoz A, Aguilera S, Alliende C, Molina C, Castro I, et al. Changes in Rab3D expression and distribution in the acini of Sjögren’s syndrome patients are associated with loss of cell polarity and secretory dysfunction. Arthritis Rheum. 2011;63(10):3126–35. https://doi.org/10.1002/art.30500.
Barrera MJ, Aguilera S, Veerman E, Quest AF, Díaz-Jiménez D, Urzúa U, et al. Salivary mucins induce a Toll-like receptor 4-mediated pro-inflammatory response in human submandibular salivary cells: are mucins involved in Sjögren’s syndrome? Rheumatology (Oxford). 2015;54(8):1518–27. https://doi.org/10.1093/rheumatology/kev026.
Sung HH, Castro I, González S, Aguilera S, Smorodinsky NI, Quest A, et al. MUC1/SEC and MUC1/Y overexpression is associated with inflammation in Sjögren’s syndrome. Oral Dis. 2015;21(6):730–8. https://doi.org/10.1111/odi.12339.
Verstappen GM, Pringle S, Bootsma H, Kroese FGM. Epithelial-immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis. Nat Rev Rheumatol. 2021;17(6):333–48. https://doi.org/10.1038/s41584-021-00605-2.
Gorgoulis V, Giatromanolaki A, Iliopoulos A, Kanavaros P, Aninos D, Ioakeimidis D, et al. EGF and EGF-r immunoexpression in Sjögren’s syndrome secondary to rheumatoid arthritis. Correlation with EBV expression? Clin Exp Rheumatol. 1993;11(6):623–7.
Sisto M, Lisi S, D’Amore M, Lofrumento DD. The metalloproteinase ADAM17 and the epidermal growth factor receptor (EGFR) signaling drive the inflammatory epithelial response in Sjögren’s syndrome. Clin Exp Med. 2015;15(2):215–25. https://doi.org/10.1007/s10238-014-0279-4.
Kajiya M, Ichimonji I, Min C, Zhu T, Jin JO, Yu Q, et al. Muscarinic type 3 receptor induces cytoprotective signaling in salivary gland cells through epidermal growth factor receptor transactivation. Mol Pharmacol. 2012;82(1):115–24. https://doi.org/10.1124/mol.111.077354.
Nakamura H, Kawakami A, Ida H, Koji T, Eguchi K. EGF activates PI3K-Akt and NF-kappaB via distinct pathways in salivary epithelial cells in Sjögren’s syndrome. Rheumatol Int. 2007;28(2):127–36. https://doi.org/10.1007/s00296-007-0411-9.
Sisto M, Ribatti D, Lisi S. E-cadherin signaling in salivary gland development and autoimmunity. J Clin Med. 2022. https://doi.org/10.3390/jcm11082241.
Sisto M, Lorusso L, Ingravallo G, Tamma R, Ribatti D, Lisi S. The TGF-β1 signaling pathway as an attractive target in the fibrosis pathogenesis of Sjögren’s syndrome. Mediators Inflamm. 2018;2018:1965935. https://doi.org/10.1155/2018/1965935.
Sisto M, Ribatti D, Lisi S. SMADS-mediate molecular mechanisms in Sjögren’s syndrome. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22063203.
Ulloa L, Doody J, Massagué J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature. 1999;397(6721):710–3. https://doi.org/10.1038/17826.
Dela Cruz A, Kartha V, Tilston-Lunel A, Mi R, Reynolds TL, Mingueneau M, et al. Gene expression alterations in salivary gland epithelia of Sjögren’s syndrome patients are associated with clinical and histopathological manifestations. Sci Rep. 2021;11(1):11154. https://doi.org/10.1038/s41598-021-90569-w.
Yin H, Cabrera-Perez J, Lai Z, Michael D, Weller M, Swaim WD, et al. Association of bone morphogenetic protein 6 with exocrine gland dysfunction in patients with Sjögren’s syndrome and in mice. Arthritis Rheum. 2013;65(12):3228–38. https://doi.org/10.1002/art.38123.
Mo YQ, Nakamura H, Tanaka T, Odani T, Perez P, Ji Y, et al. Lysosomal exocytosis of HSP70 stimulates monocytic BMP6 expression in Sjögren’s syndrome. J Clin Invest. 2022. https://doi.org/10.1172/jci152780.
Nakamura H, Tanaka T, Pranzatelli T, Ji Y, Yin H, Perez P, et al. Lysosome-associated membrane protein 3 misexpression in salivary glands induces a Sjögren’s syndrome-like phenotype in mice. Ann Rheum Dis. 2021;80(8):1031–9. https://doi.org/10.1136/annrheumdis-2020-219649.
Kang BK, Zhu Z, Wang J, Zhou J, Yu S, Zhou X, et al. Maintenance of adult stem cells from human minor salivary glands via the Wnt signaling pathway. Stem Cell Res Ther. 2023;14(1):220. https://doi.org/10.1186/s13287-023-03445-x.
Karataş A, Ömercikoğlu Z, Öz B, Dağlı AF, Çatak O, Erman F, et al. Wnt signaling pathway activities may be altered in primary Sjogren’s syndrome. Turk J Med Sci. 2021;51(4):2015–22. https://doi.org/10.3906/sag-2102-367.
Fernández-Torres J, Pérez-Hernández N, Hernández-Molina G, Martínez-Nava GA, Garrido-Rodríguez D, López-Reyes A, et al. Risk of Wnt/β-catenin signalling pathway gene polymorphisms in primary Sjögren’s syndrome. Rheumatology (Oxford). 2020;59(2):418–25. https://doi.org/10.1093/rheumatology/kez269.
Ramos-Ramírez P, Malmhäll C, Tliba O, Rådinger M, Bossios A. Adiponectin/AdipoR1 axis promotes IL-10 release by human regulatory T cells. Front Immunol. 2021;12: 677550. https://doi.org/10.3389/fimmu.2021.677550.
Katsiougiannis S, Kapsogeorgou EK, Manoussakis MN, Skopouli FN. Salivary gland epithelial cells: a new source of the immunoregulatory hormone adiponectin. Arthritis Rheum. 2006;54(7):2295–9. https://doi.org/10.1002/art.21944.
Varelas X, Wrana JL. Coordinating developmental signaling: novel roles for the Hippo pathway. Trends Cell Biol. 2012;22(2):88–96. https://doi.org/10.1016/j.tcb.2011.10.002.
Enger TB, Samad-Zadeh A, Bouchie MP, Skarstein K, Galtung HK, Mera T, et al. The Hippo signaling pathway is required for salivary gland development and its dysregulation is associated with Sjogren’s syndrome. Lab Invest. 2013;93(11):1203–18. https://doi.org/10.1038/labinvest.2013.114.
Shibata Y, Hishikawa Y, Izumi S, Fujita S, Yamaguchi A, Koji T. Involvement of Fas/Fas ligand in the induction of apoptosis in chronic sialadenitis of minor salivary glands including Sjögren’s syndrome. Hum Cell. 2002;15(1):52–60. https://doi.org/10.1111/j.1749-0774.2002.tb00099.x.
Nakamura H, Koji T, Tominaga M, Kawakami A, Migita K, Kawabe Y, et al. Apoptosis in labial salivary glands from Sjögren’s syndrome (SS) patients: comparison with human T lymphotropic virus-I (HTLV-I)-seronegative and -seropositive SS patients. Clin Exp Immunol. 1998;114(1):106–12. https://doi.org/10.1046/j.1365-2249.1998.00692.x.
Ping L, Ogawa N, Sugai S. Novel role of CD40 in Fas-dependent apoptosis of cultured salivary epithelial cells from patients with Sjögren’s syndrome. Arthritis Rheum. 2005;52(2):573–81. https://doi.org/10.1002/art.20789.
Kang Y, Sun Y, Zhang Y, Wang Z. Cytochrome c is important in apoptosis of labial glands in primary Sjogren’s syndrome. Mol Med Rep. 2018;17(1):1993–7. https://doi.org/10.3892/mmr.2017.8083.
Katsiougiannis S, Tenta R, Skopouli FN. Endoplasmic reticulum stress causes autophagy and apoptosis leading to cellular redistribution of the autoantigens Ro/Sjögren’s syndrome-related antigen A (SSA) and La/SSB in salivary gland epithelial cells. Clin Exp Immunol. 2015;181(2):244–52. https://doi.org/10.1111/cei.12638.
Tanaka T, Warner BM, Odani T, Ji Y, Mo YQ, Nakamura H, et al. LAMP3 induces apoptosis and autoantigen release in Sjögren’s syndrome patients. Sci Rep. 2020;10(1):15169. https://doi.org/10.1038/s41598-020-71669-5.
Huang L, Liu Q, Zhou T, Zhang J, Tian Q, Zhang Q, et al. Deficiency of β-arrestin2 alleviates apoptosis through GRP78-ATF6-CHOP signaling pathway in primary Sjögren’s syndrome. Int Immunopharmacol. 2021;101(Pt A): 108281. https://doi.org/10.1016/j.intimp.2021.108281.
Fujihara T, Fujita H, Tsubota K, Saito K, Tsuzaka K, Abe T, et al. Preferential localization of CD8+ alpha E beta 7+ T cells around acinar epithelial cells with apoptosis in patients with Sjögren’s syndrome. J Immunol. 1999;163(4):2226–35.
Varin MM, Guerrier T, Devauchelle-Pensec V, Jamin C, Youinou P, Pers JO. In Sjögren’s syndrome, B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase C delta activation. Autoimmun Rev. 2012;11(4):252–8. https://doi.org/10.1016/j.autrev.2011.10.005.
Reina S, Sterin-Borda L, Borda E. Anti-M(3) peptide IgG from Sjögren’s syndrome triggers apoptosis in A253 cells. Cell Immunol. 2012;275(1–2):33–41. https://doi.org/10.1016/j.cellimm.2012.03.006.
Sisto M, Lisi S, Lofrumento D, D’Amore M, Scagliusi P, Mitolo V. Autoantibodies from Sjögren’s syndrome trigger apoptosis in salivary gland cell line. Ann N Y Acad Sci. 2007;1108:418–25. https://doi.org/10.1196/annals.1422.044.
Jauharoh SN, Saegusa J, Sugimoto T, Ardianto B, Kasagi S, Sugiyama D, et al. SS-A/Ro52 promotes apoptosis by regulating Bcl-2 production. Biochem Biophys Res Commun. 2012;417(1):582–7. https://doi.org/10.1016/j.bbrc.2011.12.010.
Zhang J, Fang L, Zhu X, Qiao Y, Yu M, Wang L, et al. Ro52/SSA sensitizes cells to death receptor-induced apoptosis by down-regulating c-FLIP(L). Cell Biol Int. 2012;36(5):463–8. https://doi.org/10.1042/cbi20110322.
Abu-Helu RF, Dimitriou ID, Kapsogeorgou EK, Moutsopoulos HM, Manoussakis MN. Induction of salivary gland epithelial cell injury in Sjogren’s syndrome: in vitro assessment of T cell-derived cytokines and Fas protein expression. J Autoimmun. 2001;17(2):141–53. https://doi.org/10.1006/jaut.2001.0524.
Ye L, Shi H, Wu S, Yu C, Wang B, Zheng L. Dysregulated interleukin 11 in primary Sjögren’s syndrome contributes to apoptosis of glandular epithelial cells. Cell Biol Int. 2020;44(1):327–35. https://doi.org/10.1002/cbin.11236.
Mei M, Qu LH, Cong X, Zhang Y, Xiang RL, Yu GY, et al. CTRP3 promotes TNF-α-induced apoptosis and barrier dysfunction in salivary epithelial cells. Cell Signal. 2021;85: 110042. https://doi.org/10.1016/j.cellsig.2021.110042.
Manoussakis MN, Spachidou MP, Maratheftis CI. Salivary epithelial cells from Sjogren’s syndrome patients are highly sensitive to anoikis induced by TLR-3 ligation. J Autoimmun. 2010;35(3):212–8. https://doi.org/10.1016/j.jaut.2010.06.010.
Nakamura H, Horai Y, Suzuki T, Okada A, Ichinose K, Yamasaki S, et al. TLR3-mediated apoptosis and activation of phosphorylated Akt in the salivary gland epithelial cells of primary Sjögren’s syndrome patients. Rheumatol Int. 2013;33(2):441–50. https://doi.org/10.1007/s00296-012-2381-9.
Horai Y, Nakamura H, Nakashima Y, Hayashi T, Kawakami A. Analysis of the downstream mediators of toll-like receptor 3-induced apoptosis in labial salivary glands in patients with Sjögren’s syndrome. Mod Rheumatol. 2016;26(1):99–104. https://doi.org/10.3109/14397595.2015.1045256.
Okuma A, Hoshino K, Ohba T, Fukushi S, Aiba S, Akira S, et al. Enhanced apoptosis by disruption of the STAT3-IκB-ζ signaling pathway in epithelial cells induces Sjögren’s syndrome-like autoimmune disease. Immunity. 2013;38(3):450–60. https://doi.org/10.1016/j.immuni.2012.11.016.
Xu T, Xie W, Ma Y, Zhou S, Zhang L, Chen J, et al. Leptin/OB-R pathway promotes IL-4 secretion from B lymphocytes and induces salivary gland epithelial cell apoptosis in Sjögren’s syndrome. Oncotarget. 2017;8(38):63417–29. https://doi.org/10.18632/oncotarget.18823.
Li P, Yang Y, Jin Y, Zhao R, Dong C, Zheng W, et al. B7–H3 participates in human salivary gland epithelial cells apoptosis through NF-κB pathway in primary Sjögren’s syndrome. J Transl Med. 2019;17(1):268. https://doi.org/10.1186/s12967-019-2017-x.
Nakamura H, Kawakami A, Yamasaki S, Nakashima T, Kamachi M, Migita K, et al. Expression and function of X chromosome-linked inhibitor of apoptosis protein in Sjögren’s syndrome. Lab Invest. 2000;80(9):1421–7. https://doi.org/10.1038/labinvest.3780149.
Mariette X, Sibilia J, Roux S, Meignin V, Janin A. A new defensive mechanism to prevent apoptosis in salivary ductal cells from patients with Sjögren’s syndrome: over-expression of p53 and p21. Rheumatology (Oxford). 2002;41(1):96–9. https://doi.org/10.1093/rheumatology/41.1.96.
Sisto M, Lorusso L, Lisi S. X-linked ectodermal dysplasia receptor (XEDAR) gene silencing prevents caspase-3-mediated apoptosis in Sjögren’s syndrome. Clin Exp Med. 2017;17(1):111–9. https://doi.org/10.1007/s10238-015-0404-z.
Stegajev V, Kouri VP, Salem A, Rozov S, Stark H, Nordström DC, et al. Activation of histamine H4 receptor inhibits TNFα/IMD-0354-induced apoptosis in human salivary NS-SV-AC cells. Apoptosis. 2014;19(12):1702–11. https://doi.org/10.1007/s10495-014-1036-6.
Zhang J, Zhu L, Shi H, Zheng H. Protective effects of miR-155-5p silencing on IFN-γ-induced apoptosis and inflammation in salivary gland epithelial cells. Exp Ther Med. 2021;22(2):882. https://doi.org/10.3892/etm.2021.10314.
Ohlsson M, Skarstein K, Bolstad AI, Johannessen AC, Jonsson R. Fas-induced apoptosis is a rare event in Sjögren’s syndrome. Lab Invest. 2001;81(1):95–105. https://doi.org/10.1038/labinvest.3780215.
Van Blokland SC, Van Helden-Meeuwsen CG, Wierenga-Wolf AF, Tielemans D, Drexhage HA, Van De Merwe JP, et al. Apoptosis and apoptosis-related molecules in the submandibular gland of the nonobese diabetic mouse model for Sjögren’s syndrome: limited role for apoptosis in the development of sialoadenitis. Lab Invest. 2003;83(1):3–11. https://doi.org/10.1097/01.lab.0000048721.21475.d1.
Pérez P, Anaya JM, Aguilera S, Urzúa U, Munroe D, Molina C, et al. Gene expression and chromosomal location for susceptibility to Sjögren’s syndrome. J Autoimmun. 2009;33(2):99–108. https://doi.org/10.1016/j.jaut.2009.05.001.
Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein response. Nat Rev Mol Cell Biol. 2020;21(8):421–38. https://doi.org/10.1038/s41580-020-0250-z.
Grootjans J, Kaser A, Kaufman RJ, Blumberg RS. The unfolded protein response in immunity and inflammation. Nat Rev Immunol. 2016;16(8):469–84. https://doi.org/10.1038/nri.2016.62.
Baban B, Liu JY, Abdelsayed R, Mozaffari MS. Reciprocal relation between GADD153 and Del-1 in regulation of salivary gland inflammation in Sjögren syndrome. Exp Mol Pathol. 2013;95(3):288–97. https://doi.org/10.1016/j.yexmp.2013.09.002.
Barrera MJ, Aguilera S, Castro I, Cortés J, Bahamondes V, Quest AFG, et al. Pro-inflammatory cytokines enhance ERAD and ATF6α pathway activity in salivary glands of Sjögren’s syndrome patients. J Autoimmun. 2016;75:68–81. https://doi.org/10.1016/j.jaut.2016.07.006.
Sepúlveda D, Barrera MJ, Castro I, Aguilera S, Carvajal P, Lagos C, et al. Impaired IRE1α/XBP-1 pathway associated to DNA methylation might contribute to salivary gland dysfunction in Sjögren’s syndrome patients. Rheumatology (Oxford). 2018;57(6):1021–32. https://doi.org/10.1093/rheumatology/key021.
Apostolou E, Moustardas P, Iwawaki T, Tzioufas AG, Spyrou G. Ablation of the chaperone protein ERdj5 results in a Sjögren’s syndrome-like phenotype in mice, consistent with an upregulated unfolded protein response in human patients. Front Immunol. 2019;10:506. https://doi.org/10.3389/fimmu.2019.00506.
Castro I, Albornoz N, Aguilera S, Barrera MJ, González S, Núñez M, et al. Aberrant MUC1 accumulation in salivary glands of Sjögren’s syndrome patients is reversed by TUDCA in vitro. Rheumatology (Oxford). 2020;59(4):742–53. https://doi.org/10.1093/rheumatology/kez316.
Shadel GS, Horvath TL. Mitochondrial ROS signaling in organismal homeostasis. Cell. 2015;163(3):560–9. https://doi.org/10.1016/j.cell.2015.10.001.
Ryo K, Yamada H, Nakagawa Y, Tai Y, Obara K, Inoue H, et al. Possible involvement of oxidative stress in salivary gland of patients with Sjogren’s syndrome. Pathobiology. 2006;73(5):252–60. https://doi.org/10.1159/000098211.
Saito I. Pathology of salivary gland dysfunction and restoration of function. Pathol Int. 2021;71(5):304–15. https://doi.org/10.1111/pin.13079.
Marchi S, Guilbaud E, Tait SWG, Yamazaki T, Galluzzi L. Mitochondrial control of inflammation. Nat Rev Immunol. 2022. https://doi.org/10.1038/s41577-022-00760-x.
Shimizu T, Nakamura H, Kawakami A. Role of the innate immunity signaling pathway in the pathogenesis of Sjögren’s syndrome. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22063090.
Papinska J, Bagavant H, Gmyrek GB, Sroka M, Tummala S, Fitzgerald KA, et al. Activation of stimulator of interferon genes (STING) and Sjögren syndrome. J Dent Res. 2018;97(8):893–900. https://doi.org/10.1177/0022034518760855.
Barrera MJ, Aguilera S, Castro I, Carvajal P, Jara D, Molina C, et al. Dysfunctional mitochondria as critical players in the inflammation of autoimmune diseases: potential role in Sjögren’s syndrome. Autoimmun Rev. 2021;20(8): 102867. https://doi.org/10.1016/j.autrev.2021.102867.
Li N, Li L, Wu M, Li Y, Yang J, Wu Y, et al. Integrated bioinformatics and validation reveal potential biomarkers associated with progression of primary Sjögren’s syndrome. Front Immunol. 2021;12: 697157. https://doi.org/10.3389/fimmu.2021.697157.
Li N, Li Y, Hu J, Wu Y, Yang J, Fan H, et al. A link between mitochondrial dysfunction and the immune microenvironment of salivary glands in primary Sjogren’s syndrome. Front Immunol. 2022;13: 845209. https://doi.org/10.3389/fimmu.2022.845209.
Lim CY, Zoncu R. The lysosome as a command-and-control center for cellular metabolism. J Cell Biol. 2016;214(6):653–64. https://doi.org/10.1083/jcb.201607005.
Serrano-Puebla A, Boya P. Lysosomal membrane permeabilization as a cell death mechanism in cancer cells. Biochem Soc Trans. 2018;46(2):207–15. https://doi.org/10.1042/bst20170130.
Tanaka T, Warner BM, Michael DG, Nakamura H, Odani T, Yin H, et al. LAMP3 inhibits autophagy and contributes to cell death by lysosomal membrane permeabilization. Autophagy. 2022;18(7):1629–47. https://doi.org/10.1080/15548627.2021.1995150.
Nakamura H, Tanaka T, Zheng C, Afione SA, Warner BM, Noguchi M, et al. Correction of LAMP3-associated salivary gland hypofunction by aquaporin gene therapy. Sci Rep. 2022;12(1):18570. https://doi.org/10.1038/s41598-022-21374-2.
Suzuki A, Iwaya C, Ogata K, Yoshioka H, Shim J, Tanida I, et al. Impaired GATE16-mediated exocytosis in exocrine tissues causes Sjögren’s syndrome-like exocrinopathy. Cell Mol Life Sci. 2022;79(6):307. https://doi.org/10.1007/s00018-022-04334-x.
Colafrancesco S, Barbati C, Priori R, Putro E, Giardina F, Gattamelata A, et al. Maladaptive autophagy in the pathogenesis of autoimmune epithelitis in Sjögren’s syndrome. Arthritis Rheumatol. 2022;74(4):654–64. https://doi.org/10.1002/art.42018.
Rocchi C, Barazzuol L, Coppes RP. The evolving definition of salivary gland stem cells. NPJ Regen Med. 2021;6(1):4. https://doi.org/10.1038/s41536-020-00115-x.
Holmberg KV, Hoffman MP. Anatomy, biogenesis and regeneration of salivary glands. Monogr Oral Sci. 2014;24:1–13. https://doi.org/10.1159/000358776.
Weng PL, Aure MH, Ovitt CE. Concise review: a critical evaluation of criteria used to define salivary gland stem cells. Stem Cells. 2019;37(9):1144–50. https://doi.org/10.1002/stem.3046.
Pringle S, Maimets M, van der Zwaag M, Stokman MA, van Gosliga D, Zwart E, et al. Human salivary gland stem cells functionally restore radiation damaged salivary glands. Stem Cells. 2016;34(3):640–52. https://doi.org/10.1002/stem.2278.
Peng X, Wu Y, Brouwer U, van Vliet T, Wang B, Demaria M, et al. Cellular senescence contributes to radiation-induced hyposalivation by affecting the stem/progenitor cell niche. Cell Death Dis. 2020;11(10):854. https://doi.org/10.1038/s41419-020-03074-9.
Hauser BR, Aure MH, Kelly MC, Hoffman MP, Chibly AM. Generation of a single-Cell RNAseq atlas of murine salivary gland development. iScience. 2020;23(12): 101838. https://doi.org/10.1016/j.isci.2020.101838.
Pringle S, Wang X, Verstappen G, Terpstra JH, Zhang CK, He A, et al. Salivary gland stem cells age prematurely in primary Sjögren’s syndrome. Arthritis Rheumatol. 2019;71(1):133–42. https://doi.org/10.1002/art.40659.
Hernandez-Segura A, Nehme J, Demaria M. Hallmarks of cellular senescence. Trends Cell Biol. 2018;28(6):436–53. https://doi.org/10.1016/j.tcb.2018.02.001.
Wang X, Bootsma H, Terpstra J, Vissink A, van der Vegt B, Spijkervet FKL, et al. Progenitor cell niche senescence reflects pathology of the parotid salivary gland in primary Sjögren’s syndrome. Rheumatology (Oxford). 2020;59(10):3003–13. https://doi.org/10.1093/rheumatology/keaa012.
Gorgoulis V, Adams PD, Alimonti A, Bennett DC, Bischof O, Bishop C, et al. Cellular senescence: defining a path forward. Cell. 2019;179(4):813–27. https://doi.org/10.1016/j.cell.2019.10.005.
Cifuentes M, Del Barrio-Díaz P, Vera-Kellet C. Pilocarpine and artificial saliva for the treatment of xerostomia and xerophthalmia in Sjögren syndrome: a double-blind randomized controlled trial. Br J Dermatol. 2018;179(5):1056–61. https://doi.org/10.1111/bjd.16442.
Sato M, Kuroda S, Mansjur KQ, Khaliunaa G, Nagata K, Horiuchi S, et al. Low-intensity pulsed ultrasound rescues insufficient salivary secretion in autoimmune sialadenitis. Arthritis Res Ther. 2015;17:278. https://doi.org/10.1186/s13075-015-0798-8.
Wang Z, Wang Y, Wang S, Zhang LR, Zhang N, Cheng Z, et al. CRISPR-Cas9 HDR system enhances AQP1 gene expression. Oncotarget. 2017;8(67):111683–96. https://doi.org/10.18632/oncotarget.22901.
Khalili S, Faustman DL, Liu Y, Sumita Y, Blank D, Peterson A, et al. Treatment for salivary gland hypofunction at both initial and advanced stages of Sjögren-like disease: a comparative study of bone marrow therapy versus spleen cell therapy with a 1-year monitoring period. Cytotherapy. 2014;16(3):412–23. https://doi.org/10.1016/j.jcyt.2013.10.006.
Acknowledgements
Figures in this review were created by Figdraw (www.figdraw.com).
Funding
This work was supported by the National Natural Science Foundation of China [grant number 82104719]; and Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Shanghai University of Traditional Chinese Medicine [grant number 2021yygm05].
Author information
Authors and Affiliations
Contributions
L.X. performed conceptualization, acquisition of funding, supervision, review and editing. J.H. performed conceptualization, acquisition of funding, investigation, original draft, review and editing. Y.F. performed investigation, original draft, visualization, review and editing. Z.Y., D.C., Z.S., and R.L. performed investigation and original draft. Y.D performed supervision, review and editing. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Hou, J., Feng, Y., Yang, Z. et al. Primary Sjögren’s syndrome: new perspectives on salivary gland epithelial cells. Eur J Med Res 29, 371 (2024). https://doi.org/10.1186/s40001-024-01967-5
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s40001-024-01967-5